LNC_CODE,TEST_NAME
12-5,AMIKACIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
10328-3,LYMPHOCYTES/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
10333-3,APPEARANCE OF CEREBRAL SPINAL FLUID
10360-6,DNA SINGLE STRAND IGG AB [UNITS/VOLUME] IN SERUM
10362-2,ENDOMYSIUM IGA AB [PRESENCE] IN SERUM
10365-5,COTININE [MASS/VOLUME] IN SERUM OR PLASMA
10366-3,COTININE [MASS/VOLUME] IN URINE
10368-9,LEAD [MASS/VOLUME] IN CAPILLARY BLOOD
10451-3,PROINSULIN [MOLES/VOLUME] IN SERUM OR PLASMA --12 HOURS FASTING
10501-5,LUTROPIN [UNITS/VOLUME] IN SERUM OR PLASMA
10535-3,DIGOXIN [MASS/VOLUME] IN SERUM OR PLASMA
10543-7,METHSUXIMIDE+NORMETHSUXIMIDE [MASS/VOLUME] IN SERUM OR PLASMA
10546-0,NORMETHSUXIMIDE [MASS/VOLUME] IN SERUM OR PLASMA
10634-4,COMPLEMENT C1 ESTERASE INHIBITOR.FUNCTIONAL/COMPLEMENT C1 ESTERASE INHIBITOR.TOTAL IN SERUM OR PLASMA
10704-5,OVA AND PARASITES IDENTIFIED IN STOOL BY LIGHT MICROSCOPY
108-1,CEFOTAXIME [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
10835-7,LIPOPROTEIN A [MASS/VOLUME] IN SERUM OR PLASMA
10839-9,TROPONIN I.CARDIAC [MASS/VOLUME] IN SERUM OR PLASMA
10886-0,FREE PSA SERUM/PLASMA
10933-0,GUAR GUM IGE AB [UNITS/VOLUME] IN SERUM
10954-6,PINE NUT IGE AB [UNITS/VOLUME] IN SERUM
10987-6,FLUCONAZOLE [MASS/VOLUME] IN SERUM OR PLASMA
10989-2,ITRACONAZOLE [MASS/VOLUME] IN SERUM OR PLASMA
109-9,CEFOTAXIME [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
10992-6,NORCLOZAPINE [MASS/VOLUME] IN SERUM OR PLASMA
11011-4,HEPATITIS C VIRUS RNA [UNITS/VOLUME] (VIRAL LOAD) IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
11034-6,ACETYLCHOLINE RECEPTOR BINDING AB
11038-7,BETA+GAMMA TOCOPHEROL [MASS/VOLUME] IN SERUM OR PLASMA
11060-1,REDUCING SUBSTANCES [PRESENCE] IN STOOL
11075-9,NORFENTANYL [MASS/VOLUME] IN URINE
11135-1,APPEARANCE OF SPUN CEREBRAL SPINAL FLUID
11153-4,HEMATOCRIT [VOLUME FRACTION] OF BODY FLUID
11183-1,MACADAMIA IGE AB [UNITS/VOLUME] IN SERUM
11193-0,PUMPKIN SEED IGE AB [UNITS/VOLUME] IN SERUM
11253-2,TACROLIMUS [MASS/VOLUME] IN BLOOD
11256-5,HAEMOPHILUS INFLUENZAE B IGG AB [MASS/VOLUME] IN SERUM
11259-9,HEPATITIS C VIRUS RNA [PRESENCE] IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
11277-1,EPITHELIAL CELLS.SQUAMOUS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
11545-1,MICROSCOPIC OBSERVATION [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY ACID FAST STAIN
11555-0,BASE EXCESS OF BLOOD
11556-8,OXYGEN (O2) PRESSURE IN BLOOD
11557-6,CARBON DIOXIDE PRESSURE IN BLOOD
11558-4,PH (ACIDITY) IN BLOOD
11572-5,RHEUMATOID FACTOR [UNITS/VOLUME] IN SERUM OR PLASMA
12173-1,NON PROSTATIC ACID PHOSPHATASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
12179-8,BASOPHILS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
12183-0,CHOLESTEROL [MASS/VOLUME] IN BODY FLUID
12187-1,CREATINE KINASE.MB/CREATINE KINASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
12190-5,CREATININE [MASS/VOLUME] IN BODY FLUID
12208-5,EOSINOPHILS/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
12209-3,EOSINOPHILS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
12228-3,TRIGLYCERIDE [MASS/VOLUME] IN BODY FLUID
12234-1,MESOTHELIAL CELLS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
12238-2,NEUTROPHILS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
12288-7,DIURETICS [IDENTIFIER] IN URINE
12347-1,METOLAZONE [PRESENCE] IN URINE
12480-0,ANGIOTENSIN CONVERTING ENZYME [ENZYMATIC ACTIVITY/VOLUME] IN CEREBRAL SPINAL FLUID
12481-8,ARSENIC.INORGANIC [MASS/VOLUME] IN URINE
12598-9,FAT.NEUTRAL [PRESENCE] IN STOOL
12723-3,INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 [MASS/VOLUME] IN SERUM OR PLASMA
12841-3,FREE/TOTAL PSA SERUM/PLASME
12914-8,BETA-N-ACETYLHEXOSAMINIDASE.A/BETA-N-ACETYLHEXOSAMINIDASE.TOTAL IN SERUM
12967-6,UREA NITROGEN [MASS/VOLUME] IN 24 HOUR URINE
13076-5,PHOSPHATIDYLETHANOLAMINE IGG AB [UNITS/VOLUME] IN SERUM
13077-3,PHOSPHATIDYLETHANOLAMINE IGM AB [UNITS/VOLUME] IN SERUM
13078-1,PHOSPHATIDYLETHANOLAMINE IGA AB [UNITS/VOLUME] IN SERUM
13079-9,PHOSPHATIDYLGLYCEROL IGG AB [UNITS/VOLUME] IN SERUM
13080-7,PHOSPHATIDYLGLYCEROL IGM AB [UNITS/VOLUME] IN SERUM
13081-5,PHOSPHATIDYLGLYCEROL IGA AB [UNITS/VOLUME] IN SERUM
13082-3,PHOSPHATIDYLINOSITOL IGG AB [UNITS/VOLUME] IN SERUM
13083-1,PHOSPHATIDYLINOSITOL IGM AB [UNITS/VOLUME] IN SERUM
13084-9,PHOSPHATIDYLINOSITOL IGA AB [UNITS/VOLUME] IN SERUM
13087-2,COMPLEMENT ALTERNATE PATHWAY AH50 [UNITS/VOLUME] IN SERUM OR PLASMA
13227-4,CORYNEBACTERIUM DIPHTHERIAE IGG AB [UNITS/VOLUME] IN SERUM
13248-0,HEPATITIS D VIRUS AB [PRESENCE] IN SERUM
13249-8,HERPES SIMPLEX VIRUS 1+2 IGG AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID
13290-2,TRYPANOSOMA CRUZI IGM AB [UNITS/VOLUME] IN SERUM
13291-0,TRYPANOSOMA CRUZI IGG AB [UNITS/VOLUME] IN SERUM
13-3,AMIKACIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
13362-9,COLLECTION DURATION OF URINE
13363-7,COLLECTION DURATION OF STOOL
133-9,CEFTAZIDIME [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
13457-7,CHOLESTEROL IN LDL [MASS/VOLUME] IN SERUM OR PLASMA BY CALCULATION
13463-5,ARSENIC/CREATININE [MASS RATIO] IN URINE
13465-0,MERCURY/CREATININE [MASS RATIO] IN URINE
13466-8,LEAD/CREATININE [MASS RATIO] IN URINE
134-7,CEFTAZIDIME [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
13485-8,BETA-2-MICROGLOBULIN/CREATININE [MASS RATIO] IN URINE
13516-0,NEUTROPHILS/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
13518-6,VARIANT LYMPHOCYTES/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
13519-4,BASOPHILS/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
13521-0,BLASTS/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
13522-8,BLASTS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
13594-7,PREKALLIKREIN (FLETCHER FACTOR) [PRESENCE] IN PLATELET POOR PLASMA
13622-6,ACETAMINOPHEN [MASS/VOLUME] IN URINE
13629-1,INTERLEUKIN 1 BETA [MASS/VOLUME] IN SERUM OR PLASMA
13636-6,RIBOSOMAL P AB [UNITS/VOLUME] IN SERUM
13722-4,CITRATE/CREATININE [MASS RATIO] IN URINE
13759-6,HOMOCYSTINE/CREATININE [MASS RATIO] IN URINE
13760-4,HOMOVANILLATE/CREATININE [MASS RATIO] IN 24 HOUR URINE
13824-8,ARSENIC/CREATININE [MASS RATIO] IN 24 HOUR URINE
13828-9,CADMIUM/CREATININE [MASS RATIO] IN 24 HOUR URINE
13829-7,COPPER/CREATININE [MASS RATIO] IN URINE
13876-8,BETA-2 TRANSFERRIN [PRESENCE] IN BODY FLUID
13917-0,COCCIDIOIDES IMMITIS AB [TITER] IN CEREBRAL SPINAL FLUID BY COMPLEMENT FIXATION
13927-9,PANCREATIC ISLET CELL AB [TITER] IN SERUM
13945-1,ERYTHROCYTES [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
13949-3,CYTOMEGALOVIRUS IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
13953-5,HEPATITIS B VIRUS E AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
13954-3,HEPATITIS B VIRUS E AG [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
13955-0,HEPATITIS C VIRUS AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
13964-2,METHYLMALONATE [MOLES/VOLUME] IN SERUM OR PLASMA
13965-9,HOMOCYSTEINE [MOLES/VOLUME] IN SERUM OR PLASMA
13967-5,SEX HORMONE BINDING GLOBULIN [MOLES/VOLUME] IN SERUM OR PLASMA
13969-1,CREATINE KINASE.MB [MASS/VOLUME] IN SERUM OR PLASMA
14038-4,PACIFIC SQUID IGE AB [UNITS/VOLUME] IN SERUM
14062-4,DEXAMETHASONE [MASS/VOLUME] IN SERUM OR PLASMA
14115-0,COLLAGEN CROSSLINKED N-TELOPEPTIDE/CREATININE [MOLAR RATIO] IN URINE
14117-6,IGG CLEARANCE/ALBUMIN CLEARANCE [RATIO] IN SERUM AND CSF
141-2,CEFTRIAXONE [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
14121-8,PYRUVATE [MOLES/VOLUME] IN BLOOD
14168-9,PALATINASE [ENZYMATIC ACTIVITY/MASS] IN TISSUE
14170-5,PITUITARY GLUCOPROTEIN HORMONE.ALPHA SUBUNIT [MASS/VOLUME] IN SERUM
14178-8,SUCRASE [ENZYMATIC ACTIVITY/MASS] IN TISSUE
14196-0,RETICULOCYTES [#/VOLUME] IN BLOOD
14199-4,CHLAMYDIA TRACHOMATIS B IGA AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
142-0,CEFTRIAXONE [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
14200-0,CHLAMYDIA TRACHOMATIS B IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
14201-8,CHLAMYDIA TRACHOMATIS B IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
14207-5,STREPTOCOCCAL DNASE B [TITER] IN SERUM
14208-3,FILARIA IGG4 AB [UNITS/VOLUME] IN SERUM
14211-7,HEPATITIS E VIRUS IGG AB [PRESENCE] IN SERUM
14212-5,HEPATITIS E VIRUS IGM AB [PRESENCE] IN SERUM
14235-6,JO-1 EXTRACTABLE NUCLEAR AB [TITER] IN SERUM
14251-3,MITOCHONDRIA M2 IGG AB [UNITS/VOLUME] IN SERUM
14282-8,ACYLCARNITINE [MOLES/VOLUME] IN SERUM OR PLASMA
14286-9,CARNITINE FREE (C0) [MOLES/VOLUME] IN SERUM OR PLASMA
14288-5,CARNITINE [MOLES/VOLUME] IN SERUM OR PLASMA
14315-6,BENZOYLECGONINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
14316-4,BENZODIAZEPINES(BZO) SCREEN IN URINE
14319-8,MICROSCOPIC OBSERVATION [IDENTIFIER] IN VAGINAL FLUID BY WET PREPARATION
14334-7,LITHIUM [MOLES/VOLUME] IN SERUM OR PLASMA
14338-8,PREALBUMIN [MASS/VOLUME] IN SERUM OR PLASMA
14382-6,MONONUCLEAR CELLS/100 LEUKOCYTES IN SYNOVIAL FLUID BY MANUAL COUNT
14627-4,BICARBONATE [MOLES/VOLUME] IN VENOUS BLOOD
14628-2,BILE ACID [MOLES/VOLUME] IN SERUM
14689-4,DELTA AMINOLEVULINATE [MOLES/TIME] IN 24 HOUR URINE
14725-6,[TYPE] OF BODY FLUID
14804-9,LACTATE DEHYDROGENASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA BY LACTATE TO PYRUVATE REACTION
14836-1,METHOTREXATE [MOLES/VOLUME] IN SERUM OR PLASMA
14875-9,PHENYLALANINE [MOLES/VOLUME] IN SERUM OR PLASMA
14882-5,PORPHOBILINOGEN [MOLES/TIME] IN 24 HOUR URINE
14883-3,PORPHYRINS [INTERPRETATION] IN SERUM OR PLASMA
14884-1,PORPHYRINS [INTERPRETATION] IN STOOL
14894-0,PROPYLENE GLYCOL [PRESENCE] IN SERUM OR PLASMA
14958-3,MICROALBUMIN/CREATININE [MASS RATIO] IN 24 HOUR URINE
14979-9,APTT IN PLATELET POOR PLASMA BY COAGULATION ASSAY
1501-6,GLUCOSE [MASS/VOLUME] IN SERUM OR PLASMA --1 HOUR POST 100 G GLUCOSE PO
15038-3,CITRATE [MOLES/VOLUME] IN SERUM OR PLASMA
15048-2,CREATINE KINASE.BB/CREATINE KINASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
15049-0,CREATINE KINASE.MM/CREATINE KINASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
15060-7,ENOLASE.NEURON SPECIFIC [MASS/VOLUME] IN SERUM OR PLASMA
15061-5,ERYTHROPOIETIN (EPO) [UNITS/VOLUME] IN SERUM OR PLASMA
15066-4,FATTY ACIDS.NONESTERIFIED [MOLES/VOLUME] IN SERUM OR PLASMA
15067-2,FOLLITROPIN [UNITS/VOLUME] IN SERUM OR PLASMA
15069-8,FRUCTOSAMINE [MOLES/VOLUME] IN SERUM OR PLASMA
15085-4,OXALATE [MOLES/VOLUME] IN SERUM OR PLASMA
15087-0,PARATHYRIN RELATED PROTEIN [MOLES/VOLUME] IN SERUM OR PLASMA
1514-9,GLUCOSE [MASS/VOLUME] IN SERUM OR PLASMA --2 HOURS POST 100 G GLUCOSE PO
15152-2,BILIRUBIN.CONJUGATED [MASS/VOLUME] IN SERUM OR PLASMA
15155-5,CALCIUM [MASS/VOLUME] IN BODY FLUID
15158-9,CHLORIDE [MOLES/VOLUME] IN STOOL
15174-6,CRYOCRIT OF SERUM BY SPUN WESTERGREN
15200-9,OSMOLALITY OF BODY FLUID
15202-5,POTASSIUM [MOLES/VOLUME] IN STOOL
15207-4,SODIUM [MOLES/VOLUME] IN STOOL
15212-4,LIPASE [ENZYMATIC ACTIVITY/VOLUME] IN BODY FLUID
15283-5,SILVER BIRCH IGE AB [UNITS/VOLUME] IN SERUM
15285-0,LONDON PLANE IGE AB [UNITS/VOLUME] IN SERUM
1530-5,GLUCOSE [MASS/VOLUME] IN SERUM OR PLASMA --3 HOURS POST 100 G GLUCOSE PO
15359-3,DRVVT ACTUAL/NORMAL (NORMALIZED LA SCREEN)
15410-4,VARICELLA ZOSTER VIRUS IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
15432-8,TESTOSTERONE FREE/TESTOSTERONE.TOTAL IN SERUM OR PLASMA
1558-6,FASTING GLUCOSE [MASS/VOLUME] IN SERUM OR PLASMA
15930-1,PERCH IGE AB RAST CLASS [PRESENCE] IN SERUM
16117-4,BABESIA MICROTI IGG AB [TITER] IN SERUM
16118-2,BABESIA MICROTI IGM AB [TITER] IN SERUM
16135-6,BETA 2 GLYCOPROTEIN 1 AB.IGG
16136-4,BETA 2 GLYCOPROTEIN 1 IGM AB [UNITS/VOLUME] IN SERUM
16142-2,FAT [MASS/TIME] IN 24 HOUR STOOL
16182-8,ALKALINE PHOSPHATASE ISOENZYMES [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA BY HEAT STABILITY
16196-8,MORPHINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16197-6,CODEINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16199-2,METHADONE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16200-8,PROPOXYPHENE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16202-4,NORDIAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16205-7,LORAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16206-5,TEMAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16207-3,MEPERIDINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16211-5,DIHYDROCODEINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16221-4,PHENOTHIAZINES [PRESENCE] IN URINE BY CONFIRMATORY METHOD
16276-8,BARTONELLA HENSELAE DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
16362-6,AMMONIA [MOLES/VOLUME] IN PLASMA
16429-3,BARBITURATES [PRESENCE] IN URINE BY CONFIRMATORY METHOD
1649-3,CALCITRIOL [MASS/VOLUME] IN SERUM OR PLASMA
16-6,AMOXICILLIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
1668-3,17-HYDROXYPROGESTERONE [MASS/VOLUME] IN SERUM OR PLASMA
16688-4,CREATINE KINASE [ENZYMATIC ACTIVITY/VOLUME] IN BODY FLUID
1674-1,18-HYDROXYCORTICOSTERONE [MASS/VOLUME] IN SERUM OR PLASMA
16855-9,FAT [MASS/TIME] IN 48 HOUR STOOL
16878-1,FRANCISELLA TULARENSIS IGM AB [UNITS/VOLUME] IN SERUM
1690-7,5'-NUCLEOTIDASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
16933-4,HEPATITIS B VIRUS CORE AB [PRESENCE] IN SERUM
1695-6,5-HYDROXYINDOLEACETATE [MASS/TIME] IN 24 HOUR URINE
16982-1,HTLV I+II AB [PRESENCE] IN SERUM BY IMMUNOBLOT
17015-9,INFLUENZA VIRUS B IGG AB [UNITS/VOLUME] IN SERUM
17016-7,INFLUENZA VIRUS B IGM AB [UNITS/VOLUME] IN SERUM
17110-8,CD11B CELLS/100 CELLS IN BLOOD
17314-6,MYELIN ASSOCIATED GLYCOPROTEIN IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
1742-6,ALANINE AMINOTRANSFERASE SERUM/PLASMA
1746-7,ALBUMIN [MASS/VOLUME] IN CEREBRAL SPINAL FLUID
1747-5,ALBUMIN [MASS/VOLUME] IN BODY FLUID
17511-7,RED DYE IGE AB [UNITS/VOLUME] IN SERUM
1751-7,ALBUMIN SERUM/PLASMA
1753-3,ALBUMIN [PRESENCE] IN URINE
17562-0,SALMONELLA SP AB [PRESENCE] IN SERUM
1757-4,ALBUMIN RENAL CLEARANCE IN 24 HOUR
1761-6,ALDOLASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1763-2,ALDOSTERONE [MASS/VOLUME] IN SERUM OR PLASMA
1764-0,ALDOSTERONE [MASS/VOLUME] IN URINE
1765-7,ALDOSTERONE [MASS/TIME] IN 24 HOUR URINE
17713-9,TOPIRAMATE SERUM/PLASMA
17719-6,TRAMADOL [MASS/VOLUME] IN URINE
1777-2,ALKALINE PHOSPHATASE.BONE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
17780-8,HELICOBACTER PYLORI AG [PRESENCE] IN STOOL BY IMMUNOASSAY
17781-6,21-HYDROXYLASE AB [UNITS/VOLUME] IN SERUM
1779-8,ALKALINE PHOSPHATASE.LIVER [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
17803-8,PLASMA CELLS/100 LEUKOCYTES IN BODY FLUID
17838-4,ALKALINE PHOSPHATASE.BONE [MASS/VOLUME] IN SERUM OR PLASMA
17842-6,CANCER AG 27-29 [UNITS/VOLUME] IN SERUM OR PLASMA
17849-1,RETICULOCYTES/100 ERYTHROCYTES IN BLOOD BY AUTOMATED COUNT
17850-9,HERPES SIMPLEX VIRUS 1 IGG AB [PRESENCE] IN SERUM
17851-7,HERPES SIMPLEX VIRUS 2 IGG AB [PRESENCE] IN SERUM
17856-6,HEMOGLOBIN A1C/HEMOGLOBIN.TOTAL IN BLOOD BY HPLC
17861-6,CALCIUM SERUM/PLASMA SERUM/PLASMA
17862-4,CALCIUM [MASS/VOLUME] IN URINE
1795-4,AMYLASE [ENZYMATIC ACTIVITY/VOLUME] IN BODY FLUID
1798-8,AMYLASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1799-6,AMYLASE [ENZYMATIC ACTIVITY/VOLUME] IN URINE
1805-1,AMYLASE.PANCREATIC [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1809-3,AMYLASE.SALIVARY [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1813-5,ALPHA GALACTOSIDASE A [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1823-4,ALPHA TOCOPHEROL [MASS/VOLUME] IN SERUM OR PLASMA
18244-4,NIACIN [MASS/VOLUME] IN SERUM OR PLASMA
1825-9,ALPHA 1 ANTITRYPSIN [MASS/VOLUME] IN SERUM OR PLASMA
18262-6,CHOLESTEROL IN LDL [MASS/VOLUME] IN SERUM OR PLASMA BY DIRECT ASSAY
18325-1,OXYMORPHONE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
18337-6,HYDROXYITRACONAZOLE [MASS/VOLUME] IN SERUM OR PLASMA
18338-4,NORTRAMADOL [MASS/VOLUME] IN URINE
1834-1,ALPHA-1-FETOPROTEIN [MASS/VOLUME] IN SERUM OR PLASMA
1836-6,ALPHA-2-RETINOL BINDING PROTEIN [MASS/VOLUME] IN SERUM OR PLASMA
18388-9,DIAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
18390-5,OPIATES [PRESENCE] IN URINE BY CONFIRMATORY METHOD
18392-1,PHENCYCLIDINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
18473-9,HYDROMORPHONE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
1848-1,ANDROSTANOLONE [MASS/VOLUME] IN SERUM OR PLASMA
18484-6,KU AB [PRESENCE] IN SERUM
18485-3,MI-2 AB [PRESENCE] IN SERUM
18488-7,CALCIUM [MASS/VOLUME] IN 24 HOUR URINE
18504-1,PP INTERVAL MEAN
18506-6,P WAVE AXIS HORIZONTAL PLANE REFERENCE BEAT
18507-4,QRS AXIS.HORIZONTAL PLANE REFERENCE BEAT
18509-0,T WAVE AXIS.HORIZONTAL PLANE REFERENCE BEAT
18510-8,ST SEGMENT AXIS.HORIZONTAL PLANE
1854-9,ANDROSTENEDIONE [MASS/VOLUME] IN SERUM OR PLASMA
185-9,CIPROFLOXACIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
186-7,CIPROFLOXACIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
1869-7,APOLIPOPROTEIN A-I [MASS/VOLUME] IN SERUM OR PLASMA
1871-3,APOLIPOPROTEIN B-100 [MASS/VOLUME] IN SERUM OR PLASMA
1874-7,APOLIPOPROTEIN B/APOLIPOPROTEIN A-I [MASS RATIO] IN SERUM OR PLASMA
1903-4,ASCORBATE [MASS/VOLUME] IN SERUM OR PLASMA
19049-6,METANEPHRINE [MASS/TIME] IN 24 HOUR URINE
19053-8,BRUCELLA SP AB [TITER] IN SERUM BY AGGLUTINATION
19075-1,CELLS COUNTED TOTAL [#] IN CEREBRAL SPINAL FLUID
19113-0,IGE [UNITS/VOLUME] IN SERUM OR PLASMA
19123-9,MAGNESIUM [MASS/VOLUME] IN SERUM OR PLASMA
19124-7,MAGNESIUM [MASS/VOLUME] IN URINE
19146-0,REFERENCE LAB TEST RESULTS
19151-0,SPECIMEN DRAWN [DATE AND TIME] OF SERUM OR PLASMA
19153-6,VOLUME IN URINE COLLECTED FOR UNSPECIFIED DURATION
19161-9,UROBILINOGEN [UNITS/VOLUME] IN URINE BY TEST STRIP
1920-8,ASPARTATE AMINOTRANSFERASE SERUM/PLASMA
19235-1,BASE EXCESS STANDARD IN ARTERIAL BLOOD BY CALCULATION
19237-7,BASE EXCESS STANDARD IN VENOUS BLOOD BY CALCULATION
19244-3,CHARACTER OF URINE
19253-4,TRICHINELLA SPIRALIS AB [PRESENCE] IN SERUM BY IMMUNOASSAY
19268-2,AMPHETAMINES SCREEN METHOD [IDENTIFIER] IN URINE
19277-3,BARBITURATES SCREEN METHOD [IDENTIFIER] IN URINE
19289-8,CANNABINOIDS [PRESENCE] IN URINE BY CONFIRMATORY METHOD
19293-0,CANNABINOIDS SCREEN METHOD [IDENTIFIER] IN URINE
19295-5,OPIATES SCREEN IN URINE
19299-7,OPIATES CUTOFF [MASS/VOLUME] IN URINE FOR SCREEN METHOD
19315-1,TRICYCLIC ANTIDEPRESSANTS [PRESENCE] IN URINE BY CONFIRMATORY METHOD
19326-8,ALPHA HYDROXYALPRAZOLAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
193-3,CLINDAMYCIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
19344-1,AMPHETAMINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
19357-3,BENZOYLECGONINE CUTOFF [MASS/VOLUME] IN URINE FOR SCREEN METHOD
194-1,CLINDAMYCIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
1942-2,BETA GALACTOSIDASE [ENZYMATIC ACTIVITY/MASS] IN TISSUE
19423-3,DEXTROMETHAMPHETAMINE [PRESENCE] IN URINE BY SCREEN METHOD
19429-0,PROPOXYPHENE [PRESENCE] IN URINE BY SCREEN METHOD
19483-7,HYDROCODONE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
1952-1,BETA-2-MICROGLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA
1953-9,BETA-2-MICROGLOBULIN [MASS/VOLUME] IN URINE
1954-7,BETA-N-ACETYLHEXOSAMINIDASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM
19550-3,METHADONE (MTD) SCREEN IN URINE
19568-5,METHYLENEDIOXYMETHAMPHETAMINE ECSTASY (MDMA) SCREEN IN URINE
19586-7,MIDAZOLAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
1959-6,BICARBONATE IN BLOOD
1960-4,BICARBONATE [MOLES/VOLUME] IN ARTERIAL BLOOD
19639-4,OXAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
19642-8,OXYCODONE (OXY) SCREEN IN URINE
19643-6,OXYCODONE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
1964-6,BICARBONATE [MOLES/VOLUME] IN URINE
1974-5,BILIRUBIN.TOTAL [MASS/VOLUME] IN BODY FLUID
1975-2,TOTAL BILIRUBIN SERUM/PLASMA
1980-2,BIOTIN [MASS/VOLUME] IN SERUM OR PLASMA
1982-8,BIOTINIDASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
1986-9,C PEPTIDE [MASS/VOLUME] IN SERUM OR PLASMA
1988-5,C REACTIVE PROTEIN [MASS/VOLUME] IN SERUM OR PLASMA
1989-3,CALCIDIOL [MASS/VOLUME] IN SERUM OR PLASMA
1992-7,CALCITONIN [MASS/VOLUME] IN SERUM OR PLASMA
19996-8,OXYGEN/INSPIRED GAS RESPIRATORY SYSTEM --ON VENTILATOR
2004-0,CALCIUM [MOLES/VOLUME] IN URINE
2006-5,CANCER AG 125 [PRESENCE] IN SERUM OR PLASMA
20095-6,TEMPERATURE DISTAL AIRWAY
2019-8,CARBON DIOXIDE [PARTIAL PRESSURE] IN ARTERIAL BLOOD
2021-4,CARBON DIOXIDE [PARTIAL PRESSURE] IN VENOUS BLOOD
2028-9,CARBON DIOXIDE SERUM/PLASMA
2039-6,CARCINOEMBRYONIC AG [MASS/VOLUME] IN SERUM OR PLASMA
20396-8,LEVOFLOXACIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
20448-7,INSULIN [UNITS/VOLUME] IN SERUM OR PLASMA
20468-5,THIAMINE [MOLES/VOLUME] IN SERUM OR PLASMA
20469-3,ACETONE [PRESENCE] IN SERUM OR PLASMA BY SCREEN METHOD
20489-1,STREPTOCOCCUS PNEUMONIAE AG [PRESENCE] IN CEREBRAL SPINAL FLUID
20495-8,GLIADIN IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
20496-6,GLIADIN IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
2053-7,CAROTENE [MASS/VOLUME] IN SERUM
20563-3,CARBOXYHEMOGLOBIN % IN BLOOD
20564-1,OXYGEN SATURATION IN BLOOD
20569-0,CREATINE KINASE.MB/CREATINE KINASE.TOTAL IN SERUM OR PLASMA
20570-8,HEMATOCRIT
20573-2,HISTOPLASMA CAPSULATUM MYCELIAL PHASE AB [TITER] IN SERUM BY COMPLEMENT FIXATION
20574-0,HISTOPLASMA CAPSULATUM YEAST PHASE AB [TITER] IN SERUM BY COMPLEMENT FIXATION
20575-7,HEPATITIS A VIRUS AB [PRESENCE] IN SERUM
20578-1,VANCOMYCIN [MASS/VOLUME] IN SERUM OR PLASMA
2058-6,CATECHOLAMINES [MASS/TIME] IN 24 HOUR URINE
20590-6,CD15 CELLS/100 CELLS IN UNSPECIFIED SPECIMEN
20624-3,CREATININE [MASS/VOLUME] IN 24 HOUR URINE
20625-0,LEAD [MASS/VOLUME] IN 24 HOUR URINE
20634-2,ALPHA AMINOBUTYRATE [MOLES/VOLUME] IN SERUM OR PLASMA
20636-7,ALANINE [MOLES/VOLUME] IN SERUM OR PLASMA
20637-5,ARGININE [MOLES/VOLUME] IN SERUM OR PLASMA
20638-3,ASPARAGINE [MOLES/VOLUME] IN SERUM OR PLASMA
20639-1,ASPARTATE [MOLES/VOLUME] IN SERUM OR PLASMA
20640-9,CITRULLINE [MOLES/VOLUME] IN SERUM OR PLASMA
20642-5,GLUTAMATE [MOLES/VOLUME] IN SERUM OR PLASMA
20643-3,GLUTAMINE [MOLES/VOLUME] IN SERUM OR PLASMA
2064-4,CERULOPLASMIN [MASS/VOLUME] IN SERUM OR PLASMA
20644-1,GLYCINE [MOLES/VOLUME] IN SERUM OR PLASMA
20645-8,HISTIDINE [MOLES/VOLUME] IN SERUM OR PLASMA
20647-4,HYDROXYPROLINE [MOLES/VOLUME] IN SERUM OR PLASMA
20648-2,ISOLEUCINE [MOLES/VOLUME] IN SERUM OR PLASMA
20649-0,LEUCINE [MOLES/VOLUME] IN SERUM OR PLASMA
20650-8,LYSINE [MOLES/VOLUME] IN SERUM OR PLASMA
20651-6,METHIONINE [MOLES/VOLUME] IN SERUM OR PLASMA
20652-4,ORNITHINE [MOLES/VOLUME] IN SERUM OR PLASMA
20655-7,PROLINE [MOLES/VOLUME] IN SERUM OR PLASMA
20656-5,SERINE [MOLES/VOLUME] IN SERUM OR PLASMA
20657-3,TAURINE [MOLES/VOLUME] IN SERUM OR PLASMA
20658-1,THREONINE [MOLES/VOLUME] IN SERUM OR PLASMA
20659-9,TRYPTOPHAN [MOLES/VOLUME] IN SERUM OR PLASMA
20660-7,TYROSINE [MOLES/VOLUME] IN SERUM OR PLASMA
20661-5,VALINE [MOLES/VOLUME] IN SERUM OR PLASMA
20663-1,TRICYCLIC ANTIDEPRESSANTS [MASS/VOLUME] IN URINE BY SCREEN METHOD
2069-3,CHLORIDE [MOLES/VOLUME] IN BLOOD
2070-1,CHLORIDE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
2075-0,CHLORIDE SERUM/PLASMA
2077-6,CHLORIDE [MOLES/VOLUME] IN SWEAT
2078-4,CHLORIDE [MOLES/VOLUME] IN URINE
20-8,AMOXICILLIN+CLAVULANATE [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
2085-9,CHOLESTEROL IN HDL [MASS/VOLUME] IN SERUM OR PLASMA
2093-3,CHOLESTEROL [MASS/VOLUME] IN SERUM OR PLASMA
2098-2,CHOLINESTERASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
20992-4,BORDETELLA PERTUSSIS AB [PRESENCE] IN UNSPECIFIED SPECIMEN
21000-5,ERYTHROCYTE DISTRIBUTION WIDTH [ENTITIC VOLUME] BY AUTOMATED COUNT
21027-8,PLATELET AGGREGATION [INTERPRETATION] IN PLATELET POOR PLASMA
21036-9,17-HYDROXYCORTICOSTEROIDS [MASS/TIME] IN 24 HOUR URINE
21038-5,17-KETOSTEROIDS [MASS/VOLUME] IN 24 HOUR URINE
21046-8,7-AMINOFLUNITRAZEPAM [MASS/VOLUME] IN SERUM OR PLASMA
21074-0,ARSENIC [MASS/VOLUME] IN 24 HOUR URINE
21108-6,BETA 2 GLYCOPROTEIN 1 AB.IGA
2111-3,CHORIOGONADOTROPIN.BETA SUBUNIT [MOLES/VOLUME] IN SERUM OR PLASMA
2112-1,CHORIOGONADOTROPIN.BETA SUBUNIT (PREGNANCY TEST) [PRESENCE] IN URINE
21194-6,CHLORIDE [MOLES/VOLUME] IN 24 HOUR URINE
21198-7,CHORIOGONADOTROPIN.BETA SUBUNIT [UNITS/VOLUME] IN SERUM OR PLASMA
21201-9,CHROMIUM [MASS/VOLUME] IN 24 HOUR URINE
21203-5,CITRATE [MASS/VOLUME] IN 24 HOUR URINE
21215-9,COLLAGEN CROSSLINKED N-TELOPEPTIDE [MOLES/VOLUME] IN SERUM
2128-7,CITRATE [MASS/VOLUME] IN URINE
21305-8,GLUCOSE [MASS/VOLUME] IN 24 HOUR URINE
2132-9,COBALAMIN (VITAMIN B12) [MASS/VOLUME] IN SERUM OR PLASMA
21347-0,HTLV I+II AB BAND PATTERN [INTERPRETATION] IN SERUM BY IMMUNOBLOT
21363-7,LEGIONELLA PNEUMOPHILA DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
21365-2,LEPTIN [MASS/VOLUME] IN SERUM OR PLASMA
21367-8,LEVOFLOXACIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
21383-5,MERCURY [MASS/VOLUME] IN 24 HOUR URINE
21394-2,MONOCYTES+MACROPHAGES/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
21396-7,MONONUCLEAR CELLS [#/VOLUME] IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
21397-5,MONONUCLEAR CELLS [#/VOLUME] IN BODY FLUID BY MANUAL COUNT
2141-0,CORTICOTROPIN [MASS/VOLUME] IN PLASMA
2143-6,CORTISOL [MASS/VOLUME] IN SERUM OR PLASMA
21458-5,PHOSPHATE [MASS/VOLUME] IN 24 HOUR URINE
21476-7,POTASSIUM [MOLES/VOLUME] IN 24 HOUR URINE
2147-7,CORTISOL FREE [MASS/TIME] IN 24 HOUR URINE
21482-5,PROTEIN [MASS/VOLUME] IN 24 HOUR URINE
21525-1,SODIUM [MOLES/VOLUME] IN 24 HOUR URINE
21565-7,TIAGABINE SERUM/PLASMA
21566-5,TOLAZAMIDE [PRESENCE] IN SERUM OR PLASMA
21567-3,TOLBUTAMIDE [PRESENCE] IN SERUM OR PLASMA
2157-6,CREATINE KINASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
21582-2,TRYPTASE [MASS/VOLUME] IN SERUM OR PLASMA
21587-1,URATE [MASS/VOLUME] IN 24 HOUR URINE
2160-0,CREATININE SERUM/PLASMA
21610-1,ZINC [MASS/VOLUME] IN 24 HOUR URINE
21613-5,CHLAMYDIA TRACHOMATIS DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
2161-8,CREATININE [MASS/VOLUME] IN URINE
2162-6,CREATININE [MASS/TIME] IN 24 HOUR URINE
21654-9,CFTR GENE MUTATIONS FOUND [IDENTIFIER] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NOMINAL
21692-9,PRSS1 GENE MUTATIONS FOUND [IDENTIFIER] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NOMINAL
21695-2,HFE GENE.P.CYS282TYR [PRESENCE] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD
21696-0,HFE GENE P.HIS63ASP [PRESENCE] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD
2179-0,CYSTINE [MASS/TIME] IN 24 HOUR URINE
2191-5,DEHYDROEPIANDROSTERONE SULFATE (DHEA-S) [MASS/VOLUME] IN SERUM OR PLASMA
2193-1,DEHYDROEPIANDROSTERONE (DHEA) [MASS/VOLUME] IN SERUM OR PLASMA
2216-0,DOPAMINE [MASS/VOLUME] IN SERUM OR PLASMA
2217-8,DOPAMINE [MASS/VOLUME] IN URINE
2218-6,DOPAMINE [MASS/TIME] IN 24 HOUR URINE
22296-8,EPSTEIN BARR VIRUS NUCLEAR AB [PRESENCE] IN SERUM
2230-1,EPINEPHRINE [MASS/VOLUME] IN PLASMA
22314-9,HEPATITIS A VIRUS IGM AB [PRESENCE] IN SERUM
22322-2,HEPATITIS B VIRUS SURFACE AB [PRESENCE] IN SERUM
2232-7,EPINEPHRINE [MASS/TIME] IN 24 HOUR URINE
2243-4,ESTRADIOL (E2) [MASS/VOLUME] IN SERUM OR PLASMA
2250-9,ESTRIOL (E3).UNCONJUGATED [MASS/VOLUME] IN SERUM OR PLASMA
225-3,DOXYCYCLINE [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
22566-4,STREPTOCOCCUS PYOGENES ENZYME AB [PRESENCE] IN SERUM
22567-2,STREPTOCOCCUS PYOGENES ENZYME AB [TITER] IN SERUM
2258-2,ESTRONE (E1) [MASS/VOLUME] IN SERUM OR PLASMA
226-1,DOXYCYCLINE [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
22641-5,GLUTAMINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22642-3,TYROSINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22643-1,THREONINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22644-9,SERINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22646-4,PHENYLALANINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22647-2,ORNITHINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22648-0,METHIONINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22649-8,VALINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22650-6,GLYCINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22651-4,LYSINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22654-8,CITRULLINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22655-5,ASPARTATE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22656-3,ARGININE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22657-1,ALANINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22659-7,ISOLEUCINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
22671-2,PHYTANATE (C16:0(CH3)4) [MOLES/VOLUME] IN SERUM OR PLASMA
22672-0,CYSTINE [MOLES/VOLUME] IN SERUM OR PLASMA
2270-7,FAT [PRESENCE] IN STOOL
2271-5,FAT [MASS/TIME] IN 72 HOUR STOOL
22761-1,PRISTANATE (C15:0(CH3)4) [MOLES/VOLUME] IN SERUM OR PLASMA
2276-4,FERRITIN [MASS/VOLUME] IN SERUM OR PLASMA
2283-0,FOLATE [MASS/VOLUME] IN RED BLOOD CELLS
2284-8,FOLATE [MASS/VOLUME] IN SERUM OR PLASMA
2324-2,GAMMA GLUTAMYL TRANSFERASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
2333-3,GASTRIN [MASS/VOLUME] IN SERUM OR PLASMA
233-7,ERYTHROMYCIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
2338-2,GLUCAGON [MASS/VOLUME] IN SERUM OR PLASMA
2339-0,GLUCOSE [MASS/VOLUME] IN BLOOD
2340-8,GLUCOSE [MASS/VOLUME] IN BLOOD BY AUTOMATED TEST STRIP
2342-4,GLUCOSE [MASS/VOLUME] IN CEREBRAL SPINAL FLUID
2344-0,GLUCOSE [MASS/VOLUME] IN BODY FLUID
2345-7,GLUCOSE LAB
2350-7,GLUCOSE [MASS/VOLUME] IN URINE
2356-4,GLUCOSE-6-PHOSPHATE DEHYDROGENASE [PRESENCE] IN RED BLOOD CELLS
2357-2,GLUCOSE-6-PHOSPHATE DEHYDROGENASE [ENZYMATIC ACTIVITY/VOLUME] IN RED BLOOD CELLS
23641-4,QUINUPRISTIN+DALFOPRISTIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
23826-1,BORDETELLA PERTUSSIS DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
23830-3,BORDETELLA PERTUSSIS TOXIN IGA AB [UNITS/VOLUME] IN SERUM
23832-9,BORDETELLA PERTUSSIS TOXIN IGM AB [UNITS/VOLUME] IN SERUM
23864-2,FLUNITRAZEPAM [MASS/VOLUME] IN SERUM OR PLASMA
23883-2,INHIBIN A [MASS/VOLUME] IN SERUM OR PLASMA
23904-6,MONOCYTES+MACROPHAGES/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
23953-3,ASPERGILLUS SP AB [TITER] IN CEREBRAL SPINAL FLUID BY COMPLEMENT FIXATION
23976-4,BLASTOMYCES DERMATITIDIS AB [TITER] IN CEREBRAL SPINAL FLUID BY COMPLEMENT FIXATION
23991-3,DENGUE VIRUS IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
23992-1,DENGUE VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
24027-5,STREPTOCOCCUS PNEUMONIAE AG [PRESENCE] IN URINE
24108-3,CANCER AG 19-9 [UNITS/VOLUME] IN SERUM OR PLASMA
24110-9,TREPONEMA PALLIDUM AB [PRESENCE] IN SERUM BY IMMUNOASSAY
24111-7,NEISSERIA GONORRHOEAE DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
24113-3,HEPATITIS B VIRUS CORE IGM AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
24119-0,CYTOMEGALOVIRUS IGM AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
24312-1,TREPONEMA PALLIDUM AB [PRESENCE] IN SERUM BY AGGLUTINATION
2431-5,HOMOCYSTINE [MASS/VOLUME] IN URINE
2436-4,HOMOVANILLATE [MASS/TIME] IN 24 HOUR URINE
24375-8,PLATELET AB [PRESENCE] IN SERUM
24377-4,PLATELET AGGREGATION ADP INDUCED [PRESENCE] IN PLATELET RICH PLASMA
24378-2,PLATELET AGGREGATION EPINEPHRINE INDUCED [PRESENCE] IN PLATELET RICH PLASMA
24379-0,PLATELET AGGREGATION COLLAGEN INDUCED [PRESENCE] IN PLATELET RICH PLASMA
24380-8,PLATELET AGGREGATION RISTOCETIN INDUCED [PRESENCE] IN PLATELET RICH PLASMA
24381-6,PLATELET AGGREGATION ARACHIDONATE INDUCED [PRESENCE] IN PLATELET RICH PLASMA
24447-5,MAGNESIUM [MASS/TIME] IN 24 HOUR URINE
24467-3,CD3+CD4+ (T4 HELPER) CELLS [#/VOLUME] IN BLOOD
2458-8,IGA [MASS/VOLUME] IN SERUM OR PLASMA
2460-4,IGD [MASS/VOLUME] IN SERUM
2462-0,IGE [MASS/VOLUME] IN SERUM
2464-6,IGG [MASS/VOLUME] IN CEREBRAL SPINAL FLUID
2465-3,IGG [MASS/VOLUME] IN SERUM OR PLASMA
2466-1,IGG SUBCLASS 1 [MASS/VOLUME] IN SERUM
2467-9,IGG SUBCLASS 2 [MASS/VOLUME] IN SERUM
2468-7,IGG SUBCLASS 3 [MASS/VOLUME] IN SERUM
2469-5,IGG SUBCLASS 4 [MASS/VOLUME] IN SERUM
2470-3,IGG/ALBUMIN [MASS RATIO] IN CEREBRAL SPINAL FLUID
2472-9,IGM [MASS/VOLUME] IN SERUM OR PLASMA
2482-8,INSULIN AB [MASS/VOLUME] IN SERUM
2483-6,INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3 [MASS/VOLUME] IN SERUM OR PLASMA
2484-4,INSULIN-LIKE GROWTH FACTOR-I [MASS/VOLUME] IN SERUM OR PLASMA
2492-7,IODINE [MASS/TIME] IN 24 HOUR URINE
2498-4,IRON [MASS/VOLUME] IN SERUM OR PLASMA
2500-7,IRON BINDING CAPACITY [MASS/VOLUME] IN SERUM OR PLASMA
25148-8,CALCIUM OXALATE CRYSTALS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
25156-1,EOSINOPHILS [PRESENCE] IN URINE SEDIMENT BY LIGHT MICROSCOPY
2524-7,LACTATE [MOLES/VOLUME] IN SERUM OR PLASMA
25296-5,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 7F IGG AB [MASS/VOLUME] IN SERUM
25303-9,ALPHA 1 ANTITRYPSIN [MASS/MASS] IN STOOL
2536-1,LACTATE DEHYDROGENASE 1/LACTATE DEHYDROGENASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
25389-8,TAENIA SOLIUM LARVA IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
2539-5,LACTATE DEHYDROGENASE 2/LACTATE DEHYDROGENASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
25416-9,HERPES VIRUS 6 IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
25419-3,MUMPS VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
25421-9,MEASLES VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
2542-9,LACTATE DEHYDROGENASE 3/LACTATE DEHYDROGENASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
2545-2,LACTATE DEHYDROGENASE 4/LACTATE DEHYDROGENASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
25474-8,METANEPHRINES [MOLES/VOLUME] IN SERUM OR PLASMA
2548-6,LACTATE DEHYDROGENASE 5/LACTATE DEHYDROGENASE.TOTAL IN SERUM OR PLASMA BY ELECTROPHORESIS
25489-6,NORMETANEPHRINE [MOLES/VOLUME] IN SERUM OR PLASMA
2571-8,TRIGLYCERIDE [MASS/VOLUME] IN SERUM OR PLASMA
25757-6,SCHISTOSOMA SP IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
2589-0,LYSOZYME [MASS/VOLUME] IN SERUM OR PLASMA
25896-2,DELTA AMINOLEVULINATE [MOLES/VOLUME] IN 24 HOUR URINE
25907-7,ELASTASE.PANCREATIC [MASS/MASS] IN STOOL
25925-9,HISTAMINE/CREATININE [MOLAR RATIO] IN 24 HOUR URINE
2601-3,MAGNESIUM [MOLES/VOLUME] IN SERUM OR PLASMA
26019-0,CREATINE KINASE.MACROMOLECULAR TYPE 1/CREATINE KINASE.TOTAL IN SERUM OR PLASMA
26020-8,CREATINE KINASE.MACROMOLECULAR TYPE 2/CREATINE KINASE.TOTAL IN SERUM OR PLASMA
26052-1,EPITHELIAL CELLS.RENAL [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
2609-6,METANEPHRINES [MASS/TIME] IN 24 HOUR URINE
2617-9,METHEMOGLOBIN/HEMOGLOBIN.TOTAL IN VENOUS BLOOD
2638-5,MYELIN BASIC PROTEIN [MASS/VOLUME] IN CEREBRAL SPINAL FLUID
2639-3,MYOGLOBIN [MASS/VOLUME] IN SERUM OR PLASMA
2640-1,MYOGLOBIN [PRESENCE] IN URINE
2641-9,MYOGLOBIN [MASS/VOLUME] IN URINE
26444-0,BASOPHILS [#/VOLUME] IN BLOOD
26450-7,EOSINOPHILS %
26474-7,LYMPHOCYTES [#/VOLUME] IN BLOOD
26478-8,LYMPHOCYTES %
26499-4,NEUTROPHILS [#/VOLUME] IN BLOOD
26511-6,NEUTROPHILS %
26586-8,ALPHA AMINOBUTYRATE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
26603-1,ASPARAGINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
26614-8,TAURINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
2666-6,NOREPINEPHRINE [MASS/VOLUME] IN PLASMA
2668-2,NOREPINEPHRINE [MASS/TIME] IN 24 HOUR URINE
26688-2,MERCURY/CREATININE [MASS RATIO] IN 24 HOUR URINE
26706-2,VANILLYLMANDELATE [MASS/VOLUME] IN 24 HOUR URINE
26707-0,ALUMINUM [MASS/TIME] IN 24 HOUR URINE
2671-6,NORMETANEPHRINE [MASS/TIME] IN 24 HOUR URINE
267-5,GENTAMICIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
268-3,GENTAMICIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
26842-5,IODINE [MASS/VOLUME] IN 24 HOUR URINE
26859-9,PHENCYCLIDINE [MASS/MASS] IN MECONIUM
26881-3,INTERLEUKIN 6 [MASS/VOLUME] IN SERUM OR PLASMA
26895-3,AMPHETAMINES [MASS/MASS] IN MECONIUM
2692-2,OSMOLALITY OF SERUM OR PLASMA
2693-0,OSMOLALITY OF STOOL
2694-8,OSMOLALITY OF 24 HOUR URINE
2695-5,OSMOLALITY OF URINE
26956-3,COCAINE [MASS/MASS] IN MECONIUM
2697-1,OSTEOCALCIN [MASS/VOLUME] IN SERUM OR PLASMA
26975-3,SCL-70 EXTRACTABLE NUCLEAR AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
2700-3,OXALATE [MASS/VOLUME] IN URINE
27009-0,COCCIDIOIDES SP IGG AB [UNITS/VOLUME] IN SERUM
2701-1,OXALATE [MASS/TIME] IN 24 HOUR URINE
2703-7,OXYGEN [PARTIAL PRESSURE] IN ARTERIAL BLOOD
27038-9,ENDOMYSIUM IGA AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
27044-7,1-METHYLHISTIDINE [MOLES/VOLUME] IN URINE
2705-2,OXYGEN [PARTIAL PRESSURE] IN VENOUS BLOOD
27057-9,SEROTONIN [MASS/VOLUME] IN SERUM
27067-8,PROPOXYPHENE [MASS/MASS] IN MECONIUM
2708-6,OXYGEN SATURATION IN ARTERIAL BLOOD
27118-9,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 6B IGG AB [MASS/VOLUME] IN SERUM
2713-6,OXYGEN SATURATION CALCULATED FROM OXYGEN PARTIAL PRESSURE IN BLOOD
27201-3,ZINC/CREATININE [MASS RATIO] IN 24 HOUR URINE
27209-6,HISTOPLASMA CAPSULATUM YEAST PHASE AB [TITER] IN CEREBRAL SPINAL FLUID BY COMPLEMENT FIXATION
2721-9,PANCREATIC POLYPEPTIDE [MASS/VOLUME] IN SERUM OR PLASMA
27220-3,HISTOPLASMA CAPSULATUM MYCELIAL PHASE AB [TITER] IN CEREBRAL SPINAL FLUID BY COMPLEMENT FIXATION
27222-9,OXALATE [MASS/VOLUME] IN 24 HOUR URINE
27266-6,HISTOPLASMA CAPSULATUM AB [TITER] IN SERUM BY IMMUNE DIFFUSION (ID)
2731-8,PARATHYRIN.INTACT [MASS/VOLUME] IN SERUM OR PLASMA
27395-3,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 18C IGG AB [MASS/VOLUME] IN SERUM
2742-5,ANGIOTENSIN CONVERTING ENZYME [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
2744-1,PH OF ARTERIAL BLOOD
2746-6,PH OF VENOUS BLOOD
2748-2,PH OF BODY FLUID
2755-7,PH OF STOOL
2756-5,PH OF URINE
2777-1,PHOSPHATE
2778-9,PHOSPHATE [MASS/VOLUME] IN URINE
27810-1,PLASMIN INHIBITOR ACTUAL/NORMAL IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
27811-9,ANTITHROMBIN ACTUAL/NORMAL IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
27812-7,ANTITHROMBIN AG ACTUAL/NORMAL IN PLATELET POOR PLASMA BY IMMUNOASSAY
27816-8,VON WILLEBRAND FACTOR (VWF) AG ACTUAL/NORMAL IN PLATELET POOR PLASMA BY IMMUNOASSAY
27820-0,PROTEIN C AG ACTUAL/NORMAL IN PLATELET POOR PLASMA BY IMMUNOASSAY
27821-8,PROTEIN S FREE AG ACTUAL/NORMAL IN PLATELET POOR PLASMA BY IMMUNOASSAY
27823-4,PROTEIN S AG ACTUAL/NORMAL IN PLATELET POOR PLASMA BY IMMUNOASSAY
27831-7,IMMUNE COMPLEX [UNITS/VOLUME] IN SERUM OR PLASMA BY C1Q BINDING ASSAY
279-0,IMIPENEM [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
27923-2,COENZYME Q10 [MASS/VOLUME] IN SERUM OR PLASMA
27948-9,HERPES SIMPLEX VIRUS 1+2 IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
28044-6,GAMMA HYDROXYBUTYRATE [MASS/VOLUME] IN URINE
28-1,AMPICILLIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
2811-8,PORPHOBILINOGEN [MOLES/VOLUME] IN URINE
2821-7,POTASSIUM [MOLES/VOLUME] IN BODY FLUID
2823-3,POTASSIUM SERUM/PLASMA
2828-2,POTASSIUM [MOLES/VOLUME] IN URINE
2829-0,POTASSIUM [MOLES/TIME] IN 24 HOUR URINE
2837-3,PREGNENOLONE [MASS/VOLUME] IN SERUM OR PLASMA
2839-9,PROGESTERONE [MASS/VOLUME] IN SERUM OR PLASMA
2842-3,PROLACTIN [MASS/VOLUME] IN SERUM OR PLASMA
28546-0,NEISSERIA MENINGITIDIS A IGG AB [MASS/VOLUME] IN SERUM BY IMMUNOASSAY
28547-8,NEISSERIA MENINGITIDIS C IGG AB [MASS/VOLUME] IN SERUM BY IMMUNOASSAY
2857-1,PSA SERUM/PLASMA
28590-8,ALPHA AMINOBUTYRATE/CREATININE [RATIO] IN URINE
28593-2,GAMMA AMINOBUTYRATE/CREATININE [RATIO] IN URINE
28594-0,3-METHYLHISTIDINE/CREATININE [RATIO] IN URINE
28595-7,TAURINE/CREATININE [RATIO] IN URINE
28598-1,ALPHA AMINOADIPATE/CREATININE [RATIO] IN URINE
28601-3,HYDROXYPROLINE/CREATININE [RATIO] IN URINE
28603-9,ASPARAGINE/CREATININE [RATIO] IN URINE
28606-2,1-METHYLHISTIDINE/CREATININE [RATIO] IN URINE
2862-1,ALBUMIN [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
2865-4,ALPHA 1 GLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
28660-9,PLASMINOGEN ACTUAL/NORMAL IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
2868-8,ALPHA 2 GLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
2871-2,BETA GLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
2874-6,GAMMA GLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
2880-3,PROTEIN [MASS/VOLUME] IN CEREBRAL SPINAL FLUID
2881-1,PROTEIN [MASS/VOLUME] IN BODY FLUID
2885-2,PROTEIN SERUM/PLASMA
2890-2,PROTEIN/CREATININE [MASS RATIO] IN URINE
2900-9,PYRIDOXINE [MASS/VOLUME] IN SERUM OR PLASMA
2915-7,RENIN [ENZYMATIC ACTIVITY/VOLUME] IN PLASMA
29158-3,OPIATES [MASS/MASS] IN MECONIUM
29159-1,METHADONE [MASS/MASS] IN MECONIUM
29160-9,BENZODIAZEPINES [MASS/MASS] IN MECONIUM
29161-7,BARBITURATES [MASS/MASS] IN MECONIUM
2923-1,RETINOL [MASS/VOLUME] IN SERUM OR PLASMA
29247-4,SIROLIMUS [MASS/VOLUME] IN BLOOD
29254-0,LINEZOLID [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
29257-3,MYCOPLASMA PNEUMONIAE DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
29266-4,COPROPORPHYRIN [MOLES/MASS] IN STOOL
29267-2,PROTOPORPHYRIN [MOLES/MASS] IN STOOL
2947-0,SODIUM [MOLES/VOLUME] IN BLOOD
29495-9,HERPES VIRUS 6 DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
29497-5,PLATELET ASSOCIATED IGG AB [PRESENCE] IN BLOOD BY FLOW CYTOMETRY (FC)
29498-3,PLATELET ASSOCIATED IGM AB [PRESENCE] IN BLOOD BY FLOW CYTOMETRY (FC)
2950-4,SODIUM [MOLES/VOLUME] IN BODY FLUID
2951-2,SODIUM SERUM/PLASMA
29512-1,BETA HYDROXYBUTYRATE [MASS/VOLUME] IN SERUM OR PLASMA
29530-3,AMPHETAMINES [PRESENCE] IN UNSPECIFIED SPECIMEN
29536-0,WEST NILE VIRUS AB.IGM
2955-3,SODIUM [MOLES/VOLUME] IN URINE
2956-1,SODIUM [MOLES/TIME] IN 24 HOUR URINE
29605-3,APPEARANCE OF SYNOVIAL FLUID
2961-1,SOMATOSTATIN [MASS/VOLUME] IN PLASMA
29620-2,ZONISAMIDE SERUM/PLASMA
2963-7,SOMATOTROPIN [MASS/VOLUME] IN SERUM OR PLASMA
29640-0,ISOMALTASE [ENZYMATIC ACTIVITY/MASS] IN TISSUE
2964-5,SPECIFIC GRAVITY OF BODY FLUID
29647-5,INTERFERON BETA AB [PRESENCE] IN SERUM OR PLASMA
29660-8,PARVOVIRUS B19 IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
29672-3,BORDETELLA PERTUSSIS IGA AB [PRESENCE] IN SERUM
29673-1,BORDETELLA PERTUSSIS IGM AB [PRESENCE] IN SERUM
29674-9,BORDETELLA PERTUSSIS IGG AB [PRESENCE] IN SERUM
29723-4,BORDETELLA PARAPERTUSSIS DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
29763-0,PROTOPORPHYRIN.ZINC [MOLAR RATIO] IN RED BLOOD CELLS
29771-3,HEMOGLOBIN.GASTROINTESTINAL [PRESENCE] IN STOOL BY IMMUNOLOGIC METHOD
2986-8,TESTOSTERONE [MASS/VOLUME] IN SERUM OR PLASMA
29891-9,HELICOBACTER PYLORI [PRESENCE] IN STOMACH BY UREA BREATH TEST
29893-5,HIV 1 AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
29-9,AMPICILLIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
2990-0,TESTOSTERONE.FREE+WEAKLY BOUND [MASS/VOLUME] IN SERUM OR PLASMA
29901-6,HTLV I+II AB [PRESENCE] IN SERUM BY IMMUNOASSAY
29904-0,TOXOPLASMA GONDII DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
29905-7,ENTAMOEBA HISTOLYTICA AG [PRESENCE] IN STOOL BY IMMUNOASSAY
29911-5,MAGNESIUM [MASS/VOLUME] IN STOOL
29912-3,MAGNESIUM [MASS/TIME] IN STOOL
2991-8,TESTOSTERONE FREE [MASS/VOLUME] IN SERUM OR PLASMA
29919-8,CHROMIUM/CREATININE [MASS RATIO] IN 24 HOUR URINE
29937-0,ALUMINUM/CREATININE [MASS RATIO] IN 24 HOUR URINE
29942-0,COPPER/CREATININE [MASS RATIO] IN 24 HOUR URINE
29943-8,LEAD/CREATININE [MASS RATIO] IN 24 HOUR URINE
29944-6,ALPHA-2-MACROGLOBULIN [MASS/VOLUME] IN UNSPECIFIED SPECIMEN
29956-0,LYSOZYME [MASS/VOLUME] IN BODY FLUID
29958-6,RIBONUCLEOPROTEIN EXTRACTABLE NUCLEAR IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
29964-4,SJOGRENS SYNDROME-A EXTRACTABLE NUCLEAR IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
29965-1,SJOGRENS SYNDROME-B EXTRACTABLE NUCLEAR IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
29966-9,CENTROMERE IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
29967-7,NEUTROPHIL CYTOPLASMIC IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
2998-3,THIAMINE [MASS/VOLUME] IN BLOOD
2999-1,THIAMINE [MASS/VOLUME] IN SERUM OR PLASMA
29992-5,EOSINOPHILS [PRESENCE] IN NOSE BY WRIGHT STAIN
29996-6,HISTONE IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
3002-3,THIOCYANATE [MASS/VOLUME] IN SERUM OR PLASMA
30047-5,HISTIDINE/CREATININE [RATIO] IN URINE
30048-3,LYSINE/CREATININE [RATIO] IN URINE
30049-1,ORNITHINE/CREATININE [RATIO] IN URINE
30051-7,HOMOCYSTINE/CREATININE [RATIO] IN URINE
30052-5,ISOLEUCINE/CREATININE [RATIO] IN URINE
30053-3,LEUCINE/CREATININE [RATIO] IN URINE
30054-1,TYROSINE/CREATININE [RATIO] IN URINE
30055-8,PHENYLALANINE/CREATININE [RATIO] IN URINE
30056-6,GLUTAMINE/CREATININE [RATIO] IN URINE
30057-4,THREONINE/CREATININE [RATIO] IN URINE
30058-2,SERINE/CREATININE [RATIO] IN URINE
30059-0,GLUTAMATE/CREATININE [RATIO] IN URINE
30061-6,ASPARTATE/CREATININE [RATIO] IN URINE
30062-4,ARGININE/CREATININE [RATIO] IN URINE
30063-2,METHIONINE/CREATININE [RATIO] IN URINE
30064-0,VALINE/CREATININE [RATIO] IN URINE
30065-7,CYSTINE/CREATININE [RATIO] IN URINE
30066-5,GLYCINE/CREATININE [RATIO] IN URINE
30067-3,PROLINE/CREATININE [RATIO] IN URINE
30068-1,ALANINE/CREATININE [RATIO] IN URINE
30078-0,WEIGHT OF STOOL
30088-9,HORSE HAIR+HORSE DANDER IGE AB [UNITS/VOLUME] IN SERUM
3013-0,THYROGLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA
30152-3,MANNOSE-BINDING PROTEIN [MASS/VOLUME] IN SERUM
30153-1,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 9V IGG AB [MASS/VOLUME] IN SERUM
30161-4,CITRULLINE/CREATININE [RATIO] IN URINE
3016-3,THYROTROPIN [UNITS/VOLUME] IN SERUM OR PLASMA
30166-3,THYROID STIMULATING IMMUNOGLOBULINS ACTUAL/NORMAL IN SERUM
30167-1,HUMAN PAPILLOMA VIRUS 16+18+31+33+35+39+45+51+52+56+58+59+68 DNA [PRESENCE] IN CERVIX BY PROBE AND SIGNAL AMPLIFICATION METHOD
30170-5,AMERICAN COCKROACH IGE AB [UNITS/VOLUME] IN SERUM
30192-9,ACETYLCHOLINE RECEPTOR MODULATION AB/ACETYLCHOLINE AB.TOTAL
30194-5,FATTY ACIDS.VERY LONG CHAIN C22:0 (DOCOSANOATE) [MOLES/VOLUME] IN SERUM OR PLASMA
30195-2,FATTY ACIDS.VERY LONG CHAIN C24:0 (TETRACOSANOATE) [MOLES/VOLUME] IN SERUM OR PLASMA
30196-0,FATTY ACIDS.VERY LONG CHAIN C24:0 (TETRACOSANOATE)/C22:0 (DOCOSANOATE) [MOLAR RATIO] IN SERUM OR PLASMA
30197-8,FATTY ACIDS.VERY LONG CHAIN C26:0 (HEXACOSANOATE) [MOLES/VOLUME] IN SERUM OR PLASMA
30198-6,FATTY ACIDS.VERY LONG CHAIN C26:0 (HEXACOSANOATE)/C22:0 (DOCOSANOATE) [MOLAR RATIO] IN SERUM OR PLASMA
30211-7,COLLECTION DURATION OF UNSPECIFIED SPECIMEN
3021-3,THYROXINE BINDING GLOBULIN [MASS/VOLUME] IN SERUM OR PLASMA
3024-7,THYROXINE (T4) FREE [MASS/VOLUME] IN SERUM OR PLASMA
30248-9,TRANSFERRIN RECEPTOR.SOLUBLE [MASS/VOLUME] IN SERUM OR PLASMA
3026-2,THYROXINE (T4) [MASS/VOLUME] IN SERUM OR PLASMA
30323-0,APTT.FACTOR SUBSTITUTION IN PLATELET POOR PLASMA BY COAGULATION ASSAY --1H POST INCUBATION WITH NORMAL PLASMA
30339-6,EPSTEIN BARR VIRUS CAPSID IGG AB [PRESENCE] IN SERUM
30341-2,ERYTHROCYTE SEDIMENTATION RATE
3034-6,TRANSFERRIN [MASS/VOLUME] IN SERUM OR PLASMA
30361-0,HIV 2 AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
30368-5,MYELOCYTES/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
30371-9,PROMYELOCYTES/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
30384-2,ERYTHROCYTE DISTRIBUTION WIDTH [ENTITIC VOLUME]
3040-3,LIPASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
30471-7,LEVETIRACETAM SERUM/PLASMA
3048-6,TRIGLYCERIDE [MASS/VOLUME] IN SERUM OR PLASMA --FASTING
3050-2,TRIIODOTHYRONINE RESIN UPTAKE (T3RU) IN SERUM OR PLASMA
3051-0,TRIIODOTHYRONINE (T3) FREE [MASS/VOLUME] IN SERUM OR PLASMA
30518-5,CHOLATE [MOLES/VOLUME] IN SERUM
30519-3,CHENODEOXYCHOLATE [MOLES/VOLUME] IN SERUM
30520-1,DEOXYCHOLATE [MOLES/VOLUME] IN SERUM
30522-7,C REACTIVE PROTEIN [MASS/VOLUME] IN SERUM OR PLASMA BY HIGH SENSITIVITY METHOD
3052-8,TRIIODOTHYRONINE (T3).REVERSE [MASS/VOLUME] IN SERUM OR PLASMA
3053-6,TRIIODOTHYRONINE (T3) [MASS/VOLUME] IN SERUM OR PLASMA
30550-8,PRISTANATE (C15:0(CH3)4)/PHYTANATE (C16:0(CH3)4) [MOLAR RATIO] IN SERUM OR PLASMA
30568-0,TOXOPLASMA GONDII IGG AB [PRESENCE] IN CEREBRAL SPINAL FLUID BY IMMUNOASSAY
30571-4,VANILLYLMANDELATE/CREATININE [MASS RATIO] IN 24 HOUR URINE
3066-8,TRYPSINOGEN [MASS/VOLUME] IN SERUM OR PLASMA
3084-1,URATE [MASS/VOLUME] IN SERUM OR PLASMA
3086-6,URATE [MASS/VOLUME] IN URINE
3087-4,URATE [MASS/TIME] IN 24 HOUR URINE
30894-0,ALDOSTERONE/RENIN [RATIO] IN PLASMA
30903-9,NEUTROPHIL OXIDATIVE BURST [PRESENCE] IN BLOOD BY FLOW CYTOMETRY (FC)
30920-3,COPPER [MASS/VOLUME] IN URINE COLLECTED FOR UNSPECIFIED DURATION
3093-2,UREA NITROGEN [MASS/VOLUME] IN BODY FLUID
30934-4,NATRIURETIC PEPTIDE B [MASS/VOLUME] IN SERUM OR PLASMA
3094-0,UREA NITROGEN SERUM/PLASMA
3095-7,UREA NITROGEN [MASS/VOLUME] IN URINE
3096-5,UREA NITROGEN [MASS/TIME] IN 24 HOUR URINE
31019-3,10-HYDROXYCARBAZEPINE [MASS/VOLUME] IN SERUM OR PLASMA
31037-5,MOXIFLOXACIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
31081-3,BENZODIAZEPINES [PRESENCE] IN MECONIUM BY SCREEN METHOD
31146-4,REAGIN AB [TITER] IN CEREBRAL SPINAL FLUID BY VDRL
31154-8,COCCIDIOIDES SP IGG AB [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOASSAY
31161-3,EPIDERMAL ALLERGEN MIX 73 (CHICKEN FEATHER+DUCK FEATHER+GOOSE FEATHER+PARROT FEATHER) IGE AB [UNITS/VOLUME] IN SERUM BY MULTIDISK
31203-3,5-HYDROXYINDOLEACETATE [MASS/VOLUME] IN 24 HOUR URINE
31208-2,SPECIMEN SOURCE [IDENTIFIER] OF UNSPECIFIED SPECIMEN
31209-0,ISLET CELL 512 AB [UNITS/VOLUME] IN SERUM
3122-9,VANILLYLMANDELATE [MASS/TIME] IN 24 HOUR URINE
3125-2,VASOACTIVE INTESTINAL PEPTIDE [MASS/VOLUME] IN SERUM OR PLASMA
3126-0,VASOPRESSIN [MASS/VOLUME] IN SERUM OR PLASMA
3128-6,VISCOSITY OF SERUM
31369-2,EPSTEIN BARR VIRUS CAPSID IGA AB [UNITS/VOLUME] IN SERUM
3142-7,BODY WEIGHT STATED
31437-7,INFLUENZA VIRUS A IGG AB [UNITS/VOLUME] IN SERUM
31438-5,INFLUENZA VIRUS A IGM AB [UNITS/VOLUME] IN SERUM
31563-0,PM-SCL EXTRACTABLE NUCLEAR AB [PRESENCE] IN SERUM
31625-7,SJOGRENS SYNDROME-A EXTRACTABLE NUCLEAR IGG AB [PRESENCE] IN SERUM
31666-1,SULFATE-3-GLUCURONYL PARAGLOBOSIDE IGM AB [UNITS/VOLUME] IN SERUM
31790-9,CRYPTOCOCCUS SP AG [PRESENCE] IN SERUM
3181-5,CARDIOLIPIN IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
3182-3,CARDIOLIPIN IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
3185-6,COAGULATION FACTOR IX INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
31859-2,INFLUENZA VIRUS A AG [PRESENCE] IN UNSPECIFIED SPECIMEN
31864-2,INFLUENZA VIRUS B AG [PRESENCE] IN UNSPECIFIED SPECIMEN
3187-2,COAGULATION FACTOR IX ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3191-4,COAGULATION FACTOR V INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3193-0,COAGULATION FACTOR V ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
31950-9,RESPIRATORY SYNCYTIAL VIRUS AG [PRESENCE] IN UNSPECIFIED SPECIMEN
3196-3,COAGULATION FACTOR VII INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
31971-5,STREPTOCOCCUS PYOGENES AG [PRESENCE] IN UNSPECIFIED SPECIMEN
3198-9,COAGULATION FACTOR VII ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32009-3,CORTISOL FREE/CREATININE [MASS RATIO] IN 24 HOUR URINE
32024-2,MAGNESIUM [MASS/VOLUME] IN 24 HOUR URINE
32031-7,PHOSPHATIDYLSERINE IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
32032-5,PHOSPHATIDYLSERINE IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
32033-3,PHOSPHATIDYLSERINE IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
32043-2,UROPORPHYRIN/CREATININE [MOLAR RATIO] IN 24 HOUR URINE
3205-2,COAGULATION FACTOR VIII AB [UNITS/VOLUME] IN PLATELET POOR PLASMA BY IMMUNOASSAY
32057-2,BUTALBITAL [PRESENCE] IN UNSPECIFIED SPECIMEN
32080-4,HYDROCODONE [PRESENCE] IN UNSPECIFIED SPECIMEN
32081-2,HYDROMORPHONE [PRESENCE] IN UNSPECIFIED SPECIMEN
32088-7,MEPERIDINE [PRESENCE] IN UNSPECIFIED SPECIMEN
32093-7,METHADONE [PRESENCE] IN UNSPECIFIED SPECIMEN
3209-4,COAGULATION FACTOR VIII ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32099-4,6-MONOACETYLMORPHINE (6-MAM) [PRESENCE] IN UNSPECIFIED SPECIMEN
32100-0,MORPHINE [PRESENCE] IN UNSPECIFIED SPECIMEN
32101-8,OXYCODONE [PRESENCE] IN UNSPECIFIED SPECIMEN
32107-5,PHENCYCLIDINE [PRESENCE] IN UNSPECIFIED SPECIMEN
32108-3,PHENOBARBITAL [PRESENCE] IN UNSPECIFIED SPECIMEN
32111-7,SECOBARBITAL [PRESENCE] IN UNSPECIFIED SPECIMEN
3216-9,COAGULATION FACTOR X INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3218-5,COAGULATION FACTOR X ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32217-2,VON WILLEBRAND FACTOR (VWF) MULTIMERS [PRESENCE] IN PLATELET POOR PLASMA
3224-3,COAGULATION FACTOR XI INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3226-8,COAGULATION FACTOR XI ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3230-0,COAGULATION FACTOR XII INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32309-7,CHOLESTEROL.TOTAL/CHOLESTEROL IN HDL [MOLAR RATIO] IN SERUM OR PLASMA
3232-6,COAGULATION FACTOR XII ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32338-6,PYRUVATE [MOLES/VOLUME] IN SERUM OR PLASMA
32363-4,JC VIRUS DNA [PRESENCE] IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
32366-7,HEPATITIS B VIRUS GENOTYPE [IDENTIFIER] IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
32399-8,MATERNAL RISK FACTORS
32401-2,10 MINUTE APGAR COLOR
32402-0,10 MINUTE APGAR HEART RATE
32403-8,10 MINUTE APGAR MUSCLE TONE
32404-6,10 MINUTE APGAR REFLEX IRRITABILITY
32405-3,10 MINUTE APGAR RESPIRATORY EFFORT
32406-1,1 MINUTE APGAR COLOR
32407-9,1 MINUTE APGAR HEART RATE
32408-7,1 MINUTE APGAR MUSCLE TONE
32409-5,1 MINUTE APGAR REFLEX IRRITABILITY
32410-3,1 MINUTE APGAR RESPIRATORY EFFORT
32411-1,5 MINUTE APGAR COLOR
32412-9,5 MINUTE APGAR HEART RATE
32413-7,5 MINUTE APGAR MUSCLE TONE
32414-5,5 MINUTE APGAR REFLEX IRRITABILITY
32415-2,5 MINUTE APGAR RESPIRATORY EFFORT
3241-7,COAGULATION FACTOR XIII COAGULUM DISSOLUTION AT 24 HOURS [PRESENCE] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3243-3,THROMBIN TIME
32546-4,GLUCOSE-6-PHOSPHATE DEHYDROGENASE [ENZYMATIC ACTIVITY/MASS] IN RED BLOOD CELLS
32552-2,PYRUVATE KINASE [ENZYMATIC ACTIVITY/MASS] IN RED BLOOD CELLS
32554-8,THIAMINE [MOLES/VOLUME] IN BLOOD
3255-7,FIBRINOGEN [MASS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32572-0,TILAPIA IGE AB [UNITS/VOLUME] IN SERUM
32623-1,PLATELET MEAN VOLUME [ENTITIC VOLUME] IN BLOOD BY AUTOMATED COUNT
32635-5,COAGULATION FACTOR II INHIBITOR [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32637-1,UREASE [PRESENCE] IN TISSUE
32650-4,NORFLUNITRAZEPAM [MASS/VOLUME] IN SERUM OR PLASMA
32655-3,METANEPHRINES/CREATININE [MASS RATIO] IN 24 HOUR URINE
32693-4,LACTATE [MOLES/VOLUME] IN BLOOD
3270-6,LMW HEPARIN [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3274-8,HEPARIN UNFRACTIONATED [UNITS/VOLUME] IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
3276-3,KININOGEN HMW [UNITS/VOLUME] IN PLATELET POOR PLASMA BY COAGULATION ASSAY
32769-2,ALPHA 1 ANTITRYPSIN PHENOTYPING [INTERPRETATION] IN SERUM OR PLASMA
32852-6,CARBAMAZEPINE FREE/CARBAMAZEPINE.TOTAL IN SERUM OR PLASMA
3289-6,PROTHROMBIN ACTIVITY ACTUAL/NORMAL IN PLATELET POOR PLASMA BY COAGULATION ASSAY
3298-7,ACETAMINOPHEN [MASS/VOLUME] IN SERUM OR PLASMA
3299-5,ACETAMINOPHEN [PRESENCE] IN URINE
33037-3,ANION GAP SERUM/PLASMA
33050-6,PSEUDOCHOLINESTERASE PHENOTYPE [IDENTIFIER] IN SERUM OR PLASMA
33057-1,HEINZ BODIES/100 ERYTHROCYTES IN BLOOD BY LIGHT MICROSCOPY
33-1,AMPICILLIN+SULBACTAM [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
33210-6,TRANSFERRIN RECEPTOR.SOLUBLE [MOLES/VOLUME] IN SERUM OR PLASMA
33247-8,WEIGHT OF SWEAT
33262-7,METAMYELOCYTES/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
33263-5,METAMYELOCYTES/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
33270-0,MICROSCOPIC OBSERVATION [IDENTIFIER] IN BUFFY COAT BY LIGHT MICROSCOPY
33282-5,CANNABINOIDS [MASS/MASS] IN MECONIUM BY CONFIRMATORY METHOD
33290-8,HISTAMINE [MOLES/VOLUME] IN URINE
3330-8,AMIODARONE [MASS/VOLUME] IN SERUM OR PLASMA
33311-2,PORPHYRINS [MOLES/VOLUME] IN SERUM OR PLASMA
3333-2,AMITRIPTYLINE [MASS/VOLUME] IN SERUM OR PLASMA
33332-8,LINEZOLID [SUSCEPTIBILITY] BY GRADIENT STRIP
33333-6,COLISTIN [SUSCEPTIBILITY] BY GRADIENT STRIP
33356-7,PROTHROMBIN TIME (PT) FACTOR SUBSTITUTION IN PLATELET POOR PLASMA BY COAGULATION ASSAY --1H POST INCUBATION WITH NORMAL PLASMA
3335-7,AMITRIPTYLINE+NORTRIPTYLINE [MASS/VOLUME] IN SERUM OR PLASMA
33358-3,PROTEIN.MONOCLONAL [MASS/VOLUME] IN SERUM OR PLASMA BY ELECTROPHORESIS
33380-7,COCCIDIOIDES SP AB [TITER] IN SERUM BY COMPLEMENT FIXATION
33386-4,SEGMENTED NEUTROPHILS/100 LEUKOCYTES IN SYNOVIAL FLUID
33421-9,ALKALINE PHOSPHATASE.OTHER FRACTIONS [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA
33475-5,ORGANIC ACIDS PATTERN [INTERPRETATION] IN SERUM OR PLASMA
33510-9,COCCIDIOIDES IMMITIS IGM AB [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOASSAY
33516-6,IMMATURE RETICULOCYTES/RETICULOCYTES.TOTAL IN BLOOD
33536-4,MISCELLANEOUS ALLERGEN IGE AB RAST CLASS [PRESENCE] IN SERUM
33771-7,PL-12 AB [PRESENCE] IN SERUM
33772-5,PL-7 AB [PRESENCE] IN SERUM
33863-2,CYSTATIN C [MASS/VOLUME] IN SERUM OR PLASMA
33887-1,PROTHROMBIN TIME (PT) FACTOR SUBSTITUTION IN PLATELET POOR PLASMA BY COAGULATION ASSAY --2H POST INCUBATION WITH NORMAL PLASMA
33890-5,APTT.FACTOR SUBSTITUTION IN PLATELET POOR PLASMA BY COAGULATION ASSAY --2H POST INCUBATION WITH NORMAL PLASMA
33905-1,TRICHOMONAS SP [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
33914-3,GLOMERULAR FILTRATION RATE/1.73 SQ M.PREDICTED [VOLUME RATE/AREA] IN SERUM OR PLASMA BY CREATININE-BASED FORMULA (MDRD)
33915-0,ANABASINE [MASS/VOLUME] IN URINE
33916-8,TRANS-3-HYDROXYCOTININE [MASS/VOLUME] IN URINE
33917-6,NORNICOTINE [MASS/VOLUME] IN URINE
33921-8,SIGNAL RECOGNITION PARTICLE (SRP) AB [PRESENCE] IN SERUM OR PLASMA
3392-8,BENZOYLECGONINE [MASS/VOLUME] IN SERUM OR PLASMA
33930-9,APTT W EXCESS HEXAGONAL PHOSPHOLIPID (STACLOT LA CONFIRM)
33935-8,CYCLIC CITRULLINATED PEPTIDE IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA
3393-6,BENZOYLECGONINE [PRESENCE] IN URINE
33944-0,IMMUNOGLOBULIN LIGHT CHAINS.LAMBDA.FREE [MASS/VOLUME] IN SERUM OR PLASMA
33959-8,PROCALCITONIN [MASS/VOLUME] IN SERUM OR PLASMA
33980-4,VOLTAGE-GATED CALCIUM CHANNEL P/Q TYPE BINDING AB [MOLES/VOLUME] IN SERUM
33982-0,CALIFORNIA WALNUT POLLEN IGE AB [UNITS/VOLUME] IN SERUM
33983-8,U1 SMALL NUCLEAR RIBONUCLEOPROTEIN IGG AB [UNITS/VOLUME] IN SERUM
3399-3,BENZTHIAZIDE [PRESENCE] IN URINE
3409-0,BUMETANIDE [PRESENCE] IN URINE
3414-0,BUPRENORPHINE [PRESENCE] IN URINE
3415-7,BUPRENORPHINE [MASS/VOLUME] IN URINE
34159-4,TAU PROTEIN [PRESENCE] IN BODY FLUID
34165-1,IMMATURE GRANULOCYTES [PRESENCE] IN BLOOD BY AUTOMATED COUNT
3422-3,CAFFEINE [MASS/VOLUME] IN SERUM OR PLASMA
34284-0,DELTA AMINOLEVULINATE [MOLES/VOLUME] IN URINE
34316-0,HISTAMINE [MOLES/VOLUME] IN SERUM OR PLASMA
34319-4,INHIBIN B [MASS/VOLUME] IN SERUM OR PLASMA
3432-2,CARBAMAZEPINE SERUM/PLASMA
3433-0,CARBAMAZEPINE FREE [MASS/VOLUME] IN SERUM OR PLASMA
34376-4,STRONGYLOIDES SP IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
34444-0,ACARBOXYPROTHROMBIN [MASS/VOLUME] IN SERUM OR PLASMA
34519-9,HFE GENE TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
34538-9,ORTHOSTATIC BLOOD PRESSURE
34578-5,BARBITURATES [PRESENCE] IN MECONIUM BY SCREEN METHOD
34590-0,VON WILLEBRAND FACTOR (VWF) CLEAVING PROTEASE INHIBITOR [PRESENCE] IN PLATELET POOR PLASMA
34694-0,VASCULAR ENDOTHELIAL GROWTH FACTOR [MASS/VOLUME] IN SERUM OR PLASMA
34716-1,COXIELLA BURNETII PHASE 1 IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
34717-9,COXIELLA BURNETII PHASE 2 IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
3478-5,CHLORTHALIDONE [PRESENCE] IN URINE
34909-2,CORTISOL FREE [MASS/VOLUME] IN 24 HOUR URINE BY HPLC
3491-8,CLOMIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
3493-4,CLOMIPRAMINE+NORCLOMIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
3494-2,CLONAZEPAM SERUM/PLASMA
3495-9,CLONIDINE [MASS/VOLUME] IN SERUM OR PLASMA
34964-7,OSMOTIC FRAGILITY [INTERPRETATION] OF RED BLOOD CELLS
34985-2,UNIDENTIFIED CELLS/100 LEUKOCYTES IN BODY FLUID
35001-7,POLYMORPHONUCLEAR CELLS [#/VOLUME] IN CEREBRAL SPINAL FLUID
35002-5,POLYMORPHONUCLEAR CELLS [#/VOLUME] IN BODY FLUID
35139-5,INTERFERON BETA AB [TITER] IN SERUM OR PLASMA
35140-3,TRANS-3-HYDROXYCOTININE [MASS/VOLUME] IN SERUM OR PLASMA
3520-4,CYCLOSPORINE [MASS/VOLUME] IN BLOOD
35275-7,MEASLES VIRUS IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
3531-1,DESIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
35317-7,THERMOACTINOMYCES VULGARIS 1 AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
3536-0,NORCLOMIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
3537-8,NORDIAZEPAM [MASS/VOLUME] IN SERUM OR PLASMA
35383-9,GALACTOMANNAN AG [UNITS/VOLUME] IN SERUM OR PLASMA
35384-7,ESTRADIOL (E2) [MASS/VOLUME] IN SERUM OR PLASMA BY HIGH SENSITIVITY METHOD
35474-6,GENE XXX TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
3548-5,DIAZEPAM [MASS/VOLUME] IN SERUM OR PLASMA
3559-2,DIGITOXIN [MASS/VOLUME] IN SERUM OR PLASMA
35644-4,METANEPHRINE/CREATININE [MASS RATIO] IN 24 HOUR URINE
35668-3,GENTAMICIN [MASS/VOLUME] IN SERUM OR PLASMA
35669-1,AMIKACIN [MASS/VOLUME] IN SERUM OR PLASMA
35670-9,TOBRAMYCIN [MASS/VOLUME] IN SERUM OR PLASMA
35698-0,METFORMIN [MASS/VOLUME] IN SERUM OR PLASMA
35703-8,ADENOSINE DEAMINASE [ENZYMATIC ACTIVITY/VOLUME] IN CEREBRAL SPINAL FLUID
35704-6,ADENOSINE DEAMINASE [ENZYMATIC ACTIVITY/VOLUME] IN PLEURAL FLUID
35741-8,PROSTATE SPECIFIC AG [MASS/VOLUME] IN SERUM OR PLASMA BY DETECTION LIMIT <= 0.01 NG/ML
35788-9,DAPTOMYCIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
35800-2,ERTAPENEM [SUSCEPTIBILITY] BY GRADIENT STRIP
35801-0,ERTAPENEM [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
35809-3,FOSFOMYCIN [SUSCEPTIBILITY] BY GRADIENT STRIP
35862-2,VORICONAZOLE [SUSCEPTIBILITY] BY GRADIENT STRIP
35867-1,ACETOACETATE [MOLES/VOLUME] IN SERUM OR PLASMA
35868-9,2-OXOISOVALERATE [MOLES/VOLUME] IN SERUM OR PLASMA
35869-7,"2-OXO,3-METHYLVALERATE [MOLES/VOLUME] IN SERUM OR PLASMA"
35870-5,2-OXOISOCAPROATE [MOLES/VOLUME] IN SERUM OR PLASMA
35871-3,SUCCINATE [MOLES/VOLUME] IN SERUM OR PLASMA
3616-0,ETHOSUXIMIDE SERUM/PLASMA
363-2,NITROFURANTOIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
3637-6,FENTANYL [MASS/VOLUME] IN URINE
3638-4,FLECAINIDE [MASS/VOLUME] IN SERUM OR PLASMA
3639-2,5-FLUOROCYTOSINE [MASS/VOLUME] IN SERUM OR PLASMA
364-0,NITROFURANTOIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
3650-9,FLUPHENAZINE [MASS/VOLUME] IN SERUM OR PLASMA
3660-8,FUROSEMIDE [PRESENCE] IN URINE
3669-9,HALOPERIDOL [MASS/VOLUME] IN SERUM OR PLASMA
3676-4,HYDROCHLOROTHIAZIDE [PRESENCE] IN URINE
3690-5,IMIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
36916-5,IMMUNOGLOBULIN LIGHT CHAINS.KAPPA.FREE [MASS/VOLUME] IN SERUM
36925-6,MEFV GENE TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
3714-3,LIDOCAINE [MASS/VOLUME] IN SERUM OR PLASMA
3801-8,METHSUXIMIDE [MASS/VOLUME] IN SERUM OR PLASMA
38166-5,WEST NILE VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
38169-9,IMMUNOGLOBULIN LIGHT CHAINS.LAMBDA.FREE [MASS/TIME] IN 24 HOUR URINE
38170-7,CD18 CELLS/100 CELLS IN UNSPECIFIED SPECIMEN
38175-6,HEPTACARBOXYLATE/CREATININE [MOLAR RATIO] IN URINE
38176-4,IMMUNOGLOBULIN LIGHT CHAINS.KAPPA.FREE [MASS/VOLUME] IN URINE
38177-2,IMMUNOGLOBULIN LIGHT CHAINS.KAPPA.FREE [MASS/TIME] IN 24 HOUR URINE
38178-0,IMMUNOGLOBULIN LIGHT CHAINS.LAMBDA.FREE [MASS/VOLUME] IN URINE
38180-6,HEPATITIS C VIRUS RNA [LOG UNITS/VOLUME] (VIRAL LOAD) IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
3819-0,MEXILETINE [MASS/VOLUME] IN SERUM OR PLASMA
38190-5,ALPHA 2 GLOBULIN [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
38230-9,CALCIUM.IONIZED [MASS/VOLUME] IN BLOOD
38256-4,CELLS COUNTED TOTAL [#] IN BODY FLUID
383-0,OXACILLIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
38348-9,HERPES VIRUS 6 DNA [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
3834-9,N-ACETYLPROCAINAMIDE [MASS/VOLUME] IN SERUM OR PLASMA
38349-7,HERPES VIRUS 6 DNA [#/VOLUME] (VIRAL LOAD) IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
38350-5,HERPES VIRUS 6 DNA [LOG #/VOLUME] (VIRAL LOAD) IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
38369-5,U1 SMALL NUCLEAR RIBONUCLEOPROTEIN IGG AB [PRESENCE] IN SERUM
38370-3,VORICONAZOLE [MASS/VOLUME] IN SERUM OR PLASMA
38380-2,HFE GENE.P.SER65CYS [PRESENCE] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD
38420-6,SOLUBLE LIVER IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
38445-3,CALPROTECTIN [MASS/MASS] IN STOOL
38459-4,CRYSTALS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
38476-8,MULLERIAN INHIBITING SUBSTANCE [MASS/VOLUME] IN SERUM OR PLASMA
38483-4,CREATININE [MASS/VOLUME] IN BLOOD
38496-6,RETINYL PALMITATE [MASS/VOLUME] IN SERUM OR PLASMA
38518-7,IMMATURE GRANULOCYTES/100 LEUKOCYTES IN BLOOD
3853-9,NICOTINE [MASS/VOLUME] IN SERUM OR PLASMA
3854-7,NICOTINE [MASS/VOLUME] IN URINE
3872-9,NORTRIPTYLINE [MASS/VOLUME] IN SERUM OR PLASMA
38997-3,WEST NILE VIRUS IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
39017-9,MYCOBACTERIUM TUBERCULOSIS TUBERCULIN STIMULATED GAMMA INTERFERON/MITOGEN STIMULATED GAMMA INTERFERON IN BLOOD
39106-0,TEMPERATURE OF SKIN
392-1,PENICILLIN G [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
3924-8,PENTOBARBITAL [MASS/VOLUME] IN SERUM OR PLASMA
39354-6,CHOLINESTERASE IN SERUM OR PLASMA --DIBUCAINE/CHOLINESTERASE
393-9,PENICILLIN G [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
3948-7,PHENOBARBITAL SERUM/PLASMA
39572-3,WEST NILE VIRUS IGG AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID BY IMMUNOASSAY
39573-1,WEST NILE VIRUS IGM AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID BY IMMUNOASSAY
3968-5,PHENYTOIN SERUM/PLASMA
3969-3,PHENYTOIN FREE [MASS/VOLUME] IN SERUM OR PLASMA
3978-4,PRIMIDONE SERUM/PLASMA
39803-2,INFLIXIMAB [MASS/VOLUME] IN SERUM OR PLASMA
3982-6,PROCAINAMIDE [MASS/VOLUME] IN SERUM OR PLASMA
40100-0,APTT IN PLATELET POOR PLASMA BY COAGULATION ASSAY --BASELINE
4024-6,SALICYLATES [MASS/VOLUME] IN SERUM OR PLASMA
4025-3,SALICYLATES [PRESENCE] IN URINE
4026-1,SALICYLATES [MASS/VOLUME] IN URINE
40381-6,METHAMPHETAMINE [PRESENCE] IN UNSPECIFIED SPECIMEN
4040-2,SULFONAMIDE [MASS/VOLUME] IN SERUM OR PLASMA
40442-6,HEART RATE --POST EXERCISE
40443-4,HEART RATE --RESTING
40469-9,HYDROFLUMETHIAZIDE [PRESENCE] IN URINE
40481-4,METHYLENEDIOXYMETHAMPHETAMINE [PRESENCE] IN UNSPECIFIED SPECIMEN
4049-3,THEOPHYLLINE [MASS/VOLUME] IN SERUM OR PLASMA
40527-4,COCAINE [PRESENCE] IN MECONIUM
40585-2,DRUGS IDENTIFIED IN UNSPECIFIED SPECIMEN BY CONFIRMATORY METHOD
40595-1,PROTHROMBIN IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA
40609-0,BENZOYLECGONINE [PRESENCE] IN UNSPECIFIED SPECIMEN
40625-6,COCAINE [PRESENCE] IN UNSPECIFIED SPECIMEN
40626-4,CODEINE [PRESENCE] IN UNSPECIFIED SPECIMEN
40631-4,NUCLEATED ERYTHROCYTES/100 LEUKOCYTES [RATIO] IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
4064-2,TRAZODONE [MASS/VOLUME] IN SERUM OR PLASMA
40653-8,MYELOCYTES/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
40658-7,PARVOVIRUS B19 IGM AB [PRESENCE] IN SERUM BY IMMUNOASSAY
40660-3,PROMYELOCYTES/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
40661-1,PROTEIN.MONOCLONAL [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
40667-8,RUBELLA VIRUS IGG AB [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
40677-7,TOXOPLASMA GONDII IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
40703-1,LACTOFERRIN [PRESENCE] IN STOOL BY IMMUNOASSAY
40727-0,HEPATITIS D VIRUS AB [PRESENCE] IN SERUM BY IMMUNOASSAY
4086-5,VALPROATE SERUM/PLASMA
40869-0,CARNITINE ESTERS/CARNITINE.FREE (C0) [MOLAR RATIO] IN SERUM OR PLASMA
4087-3,VALPROATE FREE [MASS/VOLUME] IN SERUM OR PLASMA
40960-7,PARIETAL CELL IGG AB [UNITS/VOLUME] IN SERUM
40969-8,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 33F IGG AB [MASS/VOLUME] IN SERUM
40973-0,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 15B IGG AB [MASS/VOLUME] IN SERUM
40974-8,STREPTOCOCCUS PNEUMONIAE DANISH SEROTYPE 19A IGG AB [MASS/VOLUME] IN SERUM
4098-0,WARFARIN [MASS/VOLUME] IN SERUM OR PLASMA
41051-4,SPINK1 GENE MUTATIONS FOUND [IDENTIFIER] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NOMINAL
41171-0,COLLAGEN CROSSLINKED C-TELOPEPTIDE [MASS/VOLUME] IN SERUM OR PLASMA
41172-8,YEAST.BUDDING [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
41223-9,WAXY CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
41226-2,VISCOSITY OF WATER
412-7,PIPERACILLIN+TAZOBACTAM [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
41282-5,NUCLEATED ERYTHROCYTES/100 LEUKOCYTES [RATIO] IN BODY FLUID BY MANUAL COUNT
41283-3,HLA-DQ8 [PRESENCE]
413-5,PIPERACILLIN+TAZOBACTAM [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
41399-7,HERPES SIMPLEX VIRUS 1+2 IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
41400-3,YERSINIA SP IGA AB [PRESENCE] IN SERUM BY IMMUNOBLOT
41401-1,YERSINIA SP IGG AB [PRESENCE] IN SERUM BY IMMUNOBLOT
41404-5,17-HYDROXYCORTICOSTEROIDS/CREATININE [MASS RATIO] IN 24 HOUR URINE
41447-4,PLASMODIUM FALCIPARUM DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
41448-2,PLASMODIUM MALARIAE DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
41449-0,PLASMODIUM OVALE DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
41450-8,PLASMODIUM VIVAX DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
41489-6,ECHOVIRUS 11 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
41491-2,ECHOVIRUS 30 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
41492-0,ECHOVIRUS 7 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
4150-9,CAFFEINE [MASS] OF DOSE
41512-5,VARICELLA ZOSTER VIRUS IGG AB [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
4152-5,CARBAMAZEPINE [MASS] OF DOSE
41617-2,NEUTROPHIL AB [PRESENCE] IN SERUM BY FLOW CYTOMETRY (FC)
41859-0,"2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE (EDDP) [PRESENCE] IN UNSPECIFIED SPECIMEN"
41871-5,VOLTAGE-GATED POTASSIUM CHANNEL AB [MOLES/VOLUME] IN SERUM
42247-7,HEMOGLOBIN PATTERN [INTERPRETATION] IN BLOOD BY HPLC NARRATIVE
42254-3,NUCLEAR AB [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
42317-8,FOSCARNET [SUSCEPTIBILITY] BY GENOTYPE METHOD
42328-5,BORDETELLA PERTUSSIS IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
42329-3,BORDETELLA PERTUSSIS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
42330-1,BORDETELLA PERTUSSIS IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
42337-6,HERPES SIMPLEX VIRUS 1 GLYCOPROTEIN G IGG AB [UNITS/VOLUME] IN SERUM
42338-4,HERPES SIMPLEX VIRUS 2 GLYCOPROTEIN G IGG AB [UNITS/VOLUME] IN SERUM
42602-3,TROPHERYMA WHIPPELII DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
42719-5,BILIRUBIN.TOTAL [MASS/VOLUME] IN BLOOD
42757-5,TROPONIN I.CARDIAC [MASS/VOLUME] IN BLOOD
42771-6,STREPTOCOCCUS PNEUMONIAE SEROTYPE IGG AB [INTERPRETATION] IN SERUM NARRATIVE
42810-2,HEMOGLOBIN [ENTITIC MASS] IN RETICULOCYTES
428-3,RIFAMPIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
42921-7,JC VIRUS DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
43182-5,SMITH EXTRACTABLE NUCLEAR AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
43227-8,OVA AND PARASITES IDENTIFIED IN STOOL BY TRICHROME STAIN
43247-6,CATECHOLAMINES/CREATININE [MASS RATIO] IN 24 HOUR URINE
4326-5,METHSUXIMIDE [MASS] OF DOSE
4332-3,MEXILETINE [MASS] OF DOSE
43396-1,CHOLESTEROL NON HDL [MASS/VOLUME] IN SERUM OR PLASMA
43595-8,METHADONE [PRESENCE] IN MECONIUM
43626-1,ACETOHEXAMIDE [PRESENCE] IN SERUM OR PLASMA
43811-9,PROPOXYPHENE [PRESENCE] IN UNSPECIFIED SPECIMEN
43834-1,TETRAHYDROCANNABINOL [PRESENCE] IN UNSPECIFIED SPECIMEN
43880-4,BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ IGA AB [PRESENCE] IN SERUM
43881-2,BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ IGG AB [PRESENCE] IN SERUM
43882-0,BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ IGM AB [PRESENCE] IN SERUM
44005-7,CHLAMYDIA TRACHOMATIS D AND K IGA AND IGG AND IGM [INTERPRETATION] IN SERUM
44008-1,HERPES SIMPLEX VIRUS 1 AND 2 IGM AB [INTERPRETATION] IN SERUM
44081-8,CHLAMYDOPHILA PSITTACI IGA AND IGG AND IGM [INTERPRETATION] IN SERUM
44099-0,GALACTOMANNAN AG [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
44288-9,5-HYDROXYINDOLEACETATE/CREATININE [MASS RATIO] IN 24 HOUR URINE
44295-4,ALDOSTERONE/CREATININE [MASS RATIO] IN 24 HOUR URINE
44357-2,GALACTOMANNAN AG [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
44446-3,BASEMENT MEMBRANE IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOFLUORESCENCE
44448-9,BETA 2 GLYCOPROTEIN 1 IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
44449-7,BETA 2 GLYCOPROTEIN 1 IGM AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
4477-6,COMPLEMENT C1 ESTERASE INHIBITOR [MASS/VOLUME] IN SERUM OR PLASMA
4478-4,COMPLEMENT C1Q [MASS/VOLUME] IN SERUM OR PLASMA
44-8,AZTREONAM [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
44828-2,TERIFLUNOMIDE [MASS/VOLUME] IN SERUM OR PLASMA
4484-2,COMPLEMENT C2 [MASS/VOLUME] IN SERUM OR PLASMA
4485-9,COMPLEMENT C3 [MASS/VOLUME] IN SERUM OR PLASMA
44871-2,HIV 1 PROVIRAL DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
44909-0,5-HYDROXYINDOLEACETATE AND CREATININE [INTERPRETATION] IN URINE
4498-2,COMPLEMENT C4 [MASS/VOLUME] IN SERUM OR PLASMA
45149-2,EJ AB [PRESENCE] IN SERUM
45152-6,OJ AB [PRESENCE] IN SERUM
45313-4,COPROPORPHYRIN 1/CREATININE [MOLAR RATIO] IN URINE
45315-9,COPROPORPHYRIN 3/CREATININE [MOLAR RATIO] IN URINE
45323-3,MYCOBACTERIUM TUBERCULOSIS TUBERCULIN STIMULATED GAMMA INTERFERON [PRESENCE] IN BLOOD
45373-8,MEDICATION ROUTE [IDENTIFIER] OF DOSE
4537-7,ERYTHROCYTE SEDIMENTATION RATE BY WESTERGREN METHOD
4542-7,HAPTOGLOBIN [MASS/VOLUME] IN SERUM OR PLASMA
4544-3,HEMATOCRIT [VOLUME FRACTION] OF BLOOD BY AUTOMATED COUNT
4546-8,HEMOGLOBIN A/HEMOGLOBIN.TOTAL IN BLOOD
4548-4,HEMOGLOBIN A1C (GLYCATED)
45-5,AZTREONAM [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
4550-0,HEMOGLOBIN A2 [MOLES/VOLUME] IN BLOOD BY CHROMATOGRAPHY COLUMN
4551-8,HEMOGLOBIN A2/HEMOGLOBIN.TOTAL IN BLOOD
4563-3,HEMOGLOBIN C/HEMOGLOBIN.TOTAL IN BLOOD
4569-0,HEMOGLOBIN D/HEMOGLOBIN.TOTAL IN BLOOD
4575-7,HEMOGLOBIN E/HEMOGLOBIN.TOTAL IN BLOOD
4576-5,HEMOGLOBIN F/HEMOGLOBIN.TOTAL IN BLOOD
46128-5,TISSUE TRANSGLUTAMINASE IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
46134-3,GRANULAR CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46135-0,HYALINE CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46137-6,TRIPLE PHOSPHATE CRYSTALS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46138-4,URATE CRYSTALS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46216-8,MYCOBACTERIUM TUBERCULOSIS TUBERCULIN STIMULATED GAMMA INTERFERON/MITOGEN STIMULATED GAMMA INTERFERON [UNITS/VOLUME] IN CONTROL BLOOD
4621-9,HEMOGLOBIN S [PRESENCE] IN BLOOD
4625-0,HEMOGLOBIN S/HEMOGLOBIN.TOTAL IN BLOOD
46266-3,MYELOPEROXIDASE AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
46267-1,PROTEINASE 3 AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
46420-6,LEUKOCYTE CLUMPS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46421-4,MUCUS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
46424-8,HEMOLYSIS INDEX OF SERUM OR PLASMA
46425-5,LIPEMIC INDEX OF SERUM OR PLASMA
46426-3,ICTERIC INDEX OF SERUM OR PLASMA
4659-9,LEUKOCYTE PHOSPHATASE [ENZYMATIC ACTIVITY/VOLUME] IN LEUKOCYTES
4667-2,OSMOTIC FRAGILITY OF RED BLOOD CELLS
46718-3,AQUAPORIN 4 RECEPTOR IGG AB [PRESENCE] IN CEREBRAL SPINAL FLUID
46722-5,ZAP70 CELLS [PRESENCE] IN BLOOD
46725-8,TROPHERYMA WHIPPELII DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
4690-4,VISCOSITY OF BLOOD
47085-6,PLASMODIUM SP DNA [PRESENCE] IN BLOOD BY PROBE AND TARGET AMPLIFICATION METHOD
47255-5,PROCOLLAGEN TYPE I.N-TERMINAL PROPEPTIDE [MASS/VOLUME] IN SERUM
47320-7,BAKER'S YEAST IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
47321-5,BAKER'S YEAST IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
47369-4,CALCITONIN [MASS/VOLUME] IN BODY FLUID
47403-1,CYP2D6 GENE TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
47405-6,EHRLICHIA CHAFFEENSIS IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
47414-8,PREGABALIN SERUM/PLASMA
47549-1,ADENOSINE DEAMINASE [ENZYMATIC ACTIVITY/MASS] IN RED BLOOD CELLS
47828-9,ADIPONECTIN [MASS/VOLUME] IN SERUM OR PLASMA
48325-5,GLIMEPRIDE [PRESENCE] IN SERUM OR PLASMA
48326-3,GLIPIZIDE [PRESENCE] IN SERUM OR PLASMA
48327-1,GLYBURIDE [PRESENCE] IN SERUM OR PLASMA
48328-9,REPAGLINIDE [PRESENCE] IN SERUM OR PLASMA
48329-7,CHLORPROPAMIDE [PRESENCE] IN SERUM OR PLASMA
48343-8,HEMOGLOBIN.OTHER/HEMOGLOBIN.TOTAL IN BLOOD
48378-4,IMMUNOGLOBULIN LIGHT CHAINS.KAPPA.FREE/IMMUNOGLOBULIN LIGHT CHAINS.LAMBDA.FREE [MASS RATIO] IN SERUM
48399-0,HERPES SIMPLEX VIRUS 1 GLYCOPROTEIN G IGG AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID
48401-4,HERPES SIMPLEX VIRUS 2 GLYCOPROTEIN G IGG AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID
48511-0,HIV 1 RNA [#/VOLUME] (VIRAL LOAD) IN SERUM OR PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD DETECTION LIMIT = 50 COPIES/ML
48595-3,VON WILLEBRAND EVALUATION [INTERPRETATION] IN PLATELET POOR PLASMA
48670-4,IGVH GENE TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
48683-7,STREPTOCOCCUS AGALACTIAE DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
48719-9,COXIELLA BURNETII PHASE 2 IGG AB [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
48720-7,COXIELLA BURNETII PHASE 1 IGG AB [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
48850-2,EHRLICHIA CHAFFEENSIS IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
49038-3,RIBOFLAVIN [MOLES/VOLUME] IN SERUM OR PLASMA
49049-0,COLLECTION TIME OF UNSPECIFIED SPECIMEN
49054-0,25-HYDROXYCALCIFEROL [MASS/VOLUME] IN SERUM OR PLASMA
49060-7,FONDAPARINUX [MASS/VOLUME] IN SERUM OR PLASMA
49103-5,WBC CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
49231-4,CHOLINESTERASE [ENZYMATIC ACTIVITY/MASS] IN RED BLOOD CELLS
49257-9,CATECHOLAMINES [INTERPRETATION] IN PLASMA NARRATIVE
49263-7,FATTY ACIDS.VERY LONG CHAIN PATTERN [INTERPRETATION] IN SERUM OR PLASMA NARRATIVE
49269-4,HOMOVANILLATE AND CREATININE [INTERPRETATION] IN URINE NARRATIVE
49275-1,IMMUNOFIXATION FOR SERUM OR PLASMA NARRATIVE
49276-9,IMMUNOFIXATION FOR URINE NARRATIVE
49292-6,PORPHYRIN FRACTIONS [INTERPRETATION] IN 24 HOUR URINE NARRATIVE
49483-1,HIV 1 [INTERPRETATION] IN SERUM OR PLASMA BY IMMUNOASSAY NARRATIVE
49487-2,NATEGLINIDE [PRESENCE] IN SERUM OR PLASMA
49548-1,DATE REFERENCE LAB TEST SENT
49549-9,REFERENCE LAB TEST METHOD
496-0,TETRACYCLINE [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
49616-6,LEGIONELLA SP DNA [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
49751-1,NORBUPRENORPHINE [MASS/VOLUME] IN URINE BY CONFIRMATORY METHOD
49752-9,BUPRENORPHINE [MASS/VOLUME] IN URINE BY CONFIRMATORY METHOD
49753-7,NORBUPRENORPHINE [MASS/VOLUME] IN URINE
497-8,TETRACYCLINE [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
4991-6,BORRELIA BURGDORFERI DNA [PRESENCE] IN UNSPECIFIED SPECIMEN BY PROBE AND TARGET AMPLIFICATION METHOD
50064-5,IDEAL BODY WEIGHT
5048-4,NUCLEAR AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5052-6,ASPERGILLUS SP AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
5053-4,ASPERGILLUS SP AB [TITER] IN SERUM BY COMPLEMENT FIXATION
50544-6,EVEROLIMUS [MASS/VOLUME] IN BLOOD
5057-5,BLASTOMYCES DERMATITIDIS AB [TITER] IN SERUM BY COMPLEMENT FIXATION
5058-3,BLASTOMYCES DERMATITIDIS AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
50595-8,PATHOLOGIST INTERPRETATION OF UNSPECIFIED SPECIMEN TESTS
5060-9,BORRELIA BURGDORFERI AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
50612-1,CHLAMYDOPHILA PNEUMONIAE IGA AND IGG AND IGM [INTERPRETATION] IN SERUM
50754-1,APTT IN POOLED PLATELET POOR PLASMA BY COAGULATION ASSAY
5076-5,CARDIOLIPIN IGA AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
508-2,TOBRAMYCIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
509-0,TOBRAMYCIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
50948-9,VANILLYLMANDELATE AND CREATININE [INTERPRETATION] IN 24 HOUR URINE NARRATIVE
50956-2,HLA-B*57:01 [PRESENCE]
5103-7,COXSACKIEVIRUS B1 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5105-2,COXSACKIEVIRUS B2 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5107-8,COXSACKIEVIRUS B3 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5109-4,COXSACKIEVIRUS B4 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5111-0,COXSACKIEVIRUS B5 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5113-6,COXSACKIEVIRUS B6 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5117-7,CRYOGLOBULIN [PRESENCE] IN SERUM
5124-3,CYTOMEGALOVIRUS IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
5126-8,CYTOMEGALOVIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5130-0,DNA DOUBLE STRAND AB [UNITS/VOLUME] IN SERUM
5133-4,STREPTOCOCCAL DNASE B [UNITS/VOLUME] IN SERUM
51385-3,PLASMA CELLS/100 LEUKOCYTES IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
5144-1,ECHOVIRUS 6 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5146-6,ECHOVIRUS 9 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5157-3,EPSTEIN BARR VIRUS CAPSID IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5159-9,EPSTEIN BARR VIRUS CAPSID IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5160-7,EPSTEIN BARR VIRUS CAPSID IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
51625-2,MALIGNANT CELLS/100 CELLS IN BODY FLUID BY MANUAL COUNT
516-5,TRIMETHOPRIM+SULFAMETHOXAZOLE [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
51699-7,ENDOMYSIUM IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
51703-7,GANGLIOSIDE GM1 IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
51729-2,GANGLIOSIDE GM1 IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
517-3,TRIMETHOPRIM+SULFAMETHOXAZOLE [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
51730-0,HERPES VIRUS 6 IGG AND IGM [INTERPRETATION] IN SERUM NARRATIVE
51731-8,OXYGEN SATURATION CALCULATED FROM OXYGEN PARTIAL PRESSURE IN VENOUS BLOOD
51733-4,OXYGEN SATURATION CALCULATED FROM OXYGEN PARTIAL PRESSURE IN ARTERIAL BLOOD
51734-2,CHLAMYDIA TRACHOMATIS L2 IGA AND IGG AND IGM [INTERPRETATION] IN SERUM
5174-8,HELICOBACTER PYLORI AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5177-1,HELICOBACTER PYLORI IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
51790-4,RBC CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
5193-8,HEPATITIS B VIRUS SURFACE AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
5195-3,HEPATITIS B VIRUS SURFACE AG [PRESENCE] IN SERUM
5211-8,HERPES VIRUS 6 IGG AB [UNITS/VOLUME] IN SERUM
5244-9,MEASLES VIRUS IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5247-2,MITOCHONDRIA AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
524-9,VANCOMYCIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
5255-5,MYCOPLASMA PNEUMONIAE IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
525-6,VANCOMYCIN [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
5256-3,MYCOPLASMA PNEUMONIAE IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5262-1,NEUTROPHIL CYTOPLASMIC AB [UNITS/VOLUME] IN SERUM BY IMMUNOFLUORESCENCE
52768-9,CLOT FORMATION [TIME] IN BLOOD BY THROMBOELASTOGRAPHY
52778-8,MAXIMUM CLOT FIRMNESS [LENGTH] IN BLOOD BY THROMBOELASTOGRAPHY
52789-5,CLOTTING TIME OF BLOOD BY THROMBOELASTOGRAPHY
5281-1,POLIO VIRUS 1 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5283-7,POLIO VIRUS 2 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5285-2,POLIO VIRUS 3 AB [TITER] IN SERUM BY NEUTRALIZATION TEST
5290-2,REAGIN AB [PRESENCE] IN CEREBRAL SPINAL FLUID BY VDRL
5291-0,REAGIN AB [UNITS/VOLUME] IN SERUM BY VDRL
5292-8,REAGIN AB [PRESENCE] IN SERUM BY VDRL
52984-2,CYTOMEGALOVIRUS IGG AB AVIDITY [RATIO] IN SERUM BY IMMUNOASSAY
53019-6,SJOGRENS SYNDROME-A EXTRACTABLE NUCLEAR 60KD AB [UNITS/VOLUME] IN SERUM
5307-4,RICKETTSIA RICKETTSII IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5308-2,RICKETTSIA RICKETTSII IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5324-9,RICKETTSIA TYPHI IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5325-6,RICKETTSIA TYPHI IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5335-5,RUBELLA VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
53557-5,NUCLEATED CELLS [#/VOLUME] IN SYNOVIAL FLUID BY MANUAL COUNT
53575-7,VAP CHOLESTEROL PANEL - SERUM OR PLASMA
53595-5,HOMOVANILLATE [MASS/VOLUME] IN 24 HOUR URINE
53612-8,URATE [MASS/VOLUME] IN BODY FLUID
53622-7,VON WILLEBRAND FACTOR (VWF) CLEAVING PROTEASE ACTUAL/NORMAL IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
5370-2,STREPTOLYSIN O AB [UNITS/VOLUME] IN SERUM OR PLASMA
53731-6,POSACONAZOLE [MASS/VOLUME] IN SERUM OR PLASMA
53765-4,ESTROGEN [MASS/VOLUME] IN SERUM OR PLASMA BY CALCULATION
53778-7,ARSENIC ORGANIC [MASS/VOLUME] IN URINE
53779-5,ARSENIC.METHYLATED [MASS/VOLUME] IN URINE
53819-9,THIOPURINE METHYLTRANSFERASE [ENZYMATIC ACTIVITY/VOLUME] IN BLOOD
53848-8,MIXED CELLULAR CASTS [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
5385-0,THYROTROPIN RECEPTOR AB [UNITS/VOLUME] IN SERUM
5386-8,TOXOCARA CANIS AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
5388-4,TOXOPLASMA GONDII IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
5389-2,TOXOPLASMA GONDII IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
5390-0,TOXOPLASMA GONDII IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
53922-1,THYROGLOBULIN [MASS/VOLUME] IN TISSUE FINE NEEDLE ASPIRATE
53935-3,CLOSTRIDIUM TETANI TOXOID IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
53962-7,ALPHA-1-FETOPROTEIN.TUMOR MARKER [MASS/VOLUME] IN SERUM OR PLASMA
53984-1,FINE SPECKLED NUCLEAR AB PATTERN [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
5404-9,VARICELLA ZOSTER VIRUS IGM AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
54457-7,BIOTINIDASE [ENZYMATIC ACTIVITY/VOLUME] IN SERUM OR PLASMA FROM NORMAL CONTROL
54905-5,NOROVIRUS GENOGROUP I RNA [PRESENCE] IN STOOL BY PROBE AND TARGET AMPLIFICATION METHOD
54906-3,NOROVIRUS GENOGROUP II RNA [PRESENCE] IN STOOL BY PROBE AND TARGET AMPLIFICATION METHOD
55159-8,URSODEOXYCHOLATE [MOLES/VOLUME] IN SERUM
55363-6,ARGATROBAN [MASS/VOLUME] IN PLATELET POOR PLASMA
55422-0,MAXIMUM HEART RATE
5568-1,ACETONE [MASS/VOLUME] IN SERUM OR PLASMA
5569-9,ACETONE [PRESENCE] IN URINE
5574-9,ALUMINUM [MASS/VOLUME] IN SERUM OR PLASMA
55793-4,NUCLEATED CELLS [#/VOLUME] IN BODY FLUID
55806-4,MYCOPHENOLATE [MASS/VOLUME] IN SERUM OR PLASMA BY LC/MS/MS
55807-2,MYCOPHENOLATE GLUCURONIDE [MASS/VOLUME] IN SERUM OR PLASMA BY LC/MS/MS
5583-0,ARSENIC [MASS/VOLUME] IN BLOOD
5586-3,ARSENIC [MASS/VOLUME] IN URINE
5587-1,ARSENIC [MASS/TIME] IN 24 HOUR URINE
55928-6,IODINE/CREATININE [MASS RATIO] IN URINE
5609-3,CADMIUM [MASS/VOLUME] IN BLOOD
5611-9,CADMIUM [MASS/VOLUME] IN URINE
5612-7,CADMIUM [MASS/TIME] IN 24 HOUR URINE
5622-6,CHROMIUM [MASS/VOLUME] IN SERUM OR PLASMA
5624-2,CHROMIUM [MASS/TIME] IN 24 HOUR URINE
5625-9,COBALT [MASS/VOLUME] IN BLOOD
5627-5,COBALT [MASS/VOLUME] IN SERUM OR PLASMA
5631-7,COPPER [MASS/VOLUME] IN SERUM OR PLASMA
5632-5,COPPER [MASS/VOLUME] IN URINE
5633-3,COPPER [MASS/TIME] IN 24 HOUR URINE
5634-1,CYANIDE [MASS/VOLUME] IN BLOOD
5643-2,ETHANOL [MASS/VOLUME] IN SERUM OR PLASMA
5644-0,ETHANOL [PRESENCE] IN URINE
5645-7,ETHANOL [MASS/VOLUME] IN URINE
5646-5,"ETHYLENE GLYCOL [MASS/VOLUME] IN SERUM, PLASMA OR BLOOD"
56537-4,TISSUE TRANSGLUTAMINASE IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
56540-8,GLUTAMATE DECARBOXYLASE 65 AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
56669-5,CAROTENE.ALPHA [MASS/VOLUME] IN SERUM
5669-7,ISOPROPANOL [MASS/VOLUME] IN SERUM OR PLASMA
5670-5,ISOPROPANOL [PRESENCE] IN URINE
5676-2,LEAD [MASS/VOLUME] IN URINE
56764-4,OLIGOCLONAL BANDS IGG [PRESENCE] IN CEREBRAL SPINAL FLUID BY ISOELECTRIC FOCUSING
5677-0,LEAD [MASS/TIME] IN 24 HOUR URINE
5681-2,MANGANESE [MASS/VOLUME] IN BLOOD
5683-8,MANGANESE [MASS/VOLUME] IN SERUM OR PLASMA
5685-3,MERCURY [MASS/VOLUME] IN BLOOD
56888-1,HIV 1+2 AB+HIV1 P24 AG [PRESENCE] IN SERUM OR PLASMA BY IMMUNOASSAY
5689-5,MERCURY [MASS/VOLUME] IN URINE
5693-7,METHANOL [MASS/VOLUME] IN SERUM OR PLASMA
5694-5,METHANOL [PRESENCE] IN URINE
57090-3,HLA-DQA1*05:01 [PRESENCE]
57091-1,HLA-DQB1*02:01 [PRESENCE]
5724-0,SELENIUM [MASS/VOLUME] IN SERUM OR PLASMA
5763-8,ZINC [MASS/VOLUME] IN SERUM OR PLASMA
5765-3,ZINC [MASS/TIME] IN 24 HOUR URINE
5769-5,BACTERIA [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
5770-3,BILIRUBIN.TOTAL [PRESENCE] IN URINE BY TEST STRIP
57723-9,UNIQUE BAR CODE NUMBER OF CURRENT SAMPLE
57779-1,DISACCHARIDASES [INTERPRETATION] IN SMALL INTESTINE TISSUE NARRATIVE
5778-6,COLOR OF URINE
57884-9,HONEYDEW MELON IGE AB [UNITS/VOLUME] IN SERUM
5792-7,GLUCOSE URINE DIPSTICK
5794-3,HEMOGLOBIN [PRESENCE] IN URINE BY TEST STRIP
5797-6,KETONES [MASS/VOLUME] IN URINE BY TEST STRIP
5799-2,LEUKOCYTE ESTERASE [PRESENCE] IN URINE BY TEST STRIP
58012-6,NATALIZUMAB AB [PRESENCE] IN SERUM
58023-3,RABIES VIRUS IGG AB [UNITS/VOLUME] IN SERUM
5802-4,NITRITE [PRESENCE] IN URINE BY TEST STRIP
5803-2,PH OF URINE BY TEST STRIP
5804-0,PROTEIN [MASS/VOLUME] IN URINE BY TEST STRIP
5808-1,ERYTHROCYTES [#/VOLUME] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
5809-9,REDUCING SUBSTANCES [PRESENCE] IN URINE
5811-5,SPECIFIC GRAVITY OF URINE BY TEST STRIP
5818-0,UROBILINOGEN [PRESENCE] IN URINE BY TEST STRIP
5821-4,LEUKOCYTES [#/AREA] IN URINE SEDIMENT BY MICROSCOPY HIGH POWER FIELD
5834-7,ADENOVIRUS AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
58365-8,7-AMINOCLONAZEPAM [PRESENCE] IN URINE BY CONFIRMATORY METHOD
58388-0,NORMEPERIDINE [PRESENCE] IN URINE BY CONFIRMATORY METHOD
58413-6,NUCLEATED ERYTHROCYTES/100 LEUKOCYTES [RATIO] IN BLOOD BY AUTOMATED COUNT
5863-6,INFLUENZA VIRUS A AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
5867-7,INFLUENZA VIRUS B AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
5869-3,PARAINFLUENZA VIRUS 1 AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
5871-9,PARAINFLUENZA VIRUS 2 AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
58722-0,LYMPHOCYTE PROLIFERATION STIMULATED BY POKEWEED MITOGEN [INTERPRETATION] IN BLOOD
5873-5,PARAINFLUENZA VIRUS 3 AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
58738-6,DRUGS OF ABUSE [INTERPRETATION] IN MECONIUM
5877-6,RESPIRATORY SYNCYTIAL VIRUS AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
5880-0,ROTAVIRUS AG [PRESENCE] IN STOOL BY IMMUNOASSAY
588-4,LEGIONELLA PNEUMOPHILA AG [PRESENCE] IN UNSPECIFIED SPECIMEN BY IMMUNOFLUORESCENCE
58906-9,NUCLEATED CELLS [#/VOLUME] IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
58929-1,HLA-DQB1*03:02 [PRESENCE]
5901-4,PROTHROMBIN TIME - CONTROL
5902-2,PROTHROMBIN TIME - PATIENT
5905-5,MONOCYTES/100 LEUKOCYTES IN BLOOD BY AUTOMATED COUNT
59063-8,LYMPHOCYTE PROLIFERATION PANEL - BLOOD
59297-2,LACOSAMIDE [MASS/VOLUME] IN SERUM OR PLASMA
59323-6,RUFINAMIDE [MASS/VOLUME] IN SERUM OR PLASMA
59387-1,TRYPANOSOMA CRUZI IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
59408-5,OXYGEN SATURATION IN ARTERIAL BLOOD BY PULSE OXIMETRY
59462-2,CLINICAL BIOCHEMIST REVIEW OF RESULTS
59464-8,MICROBIOLOGIST REVIEW OF RESULTS
59465-5,PATHOLOGIST REVIEW OF RESULTS
5959-2,PROTHROMBIN TIME (PT) FACTOR SUBSTITUTION IN PLATELET POOR PLASMA BY COAGULATION ASSAY --IMMEDIATELY AFTER ADDITION OF NORMAL PLASMA
5975-8,PLASMINOGEN ACTIVATOR INHIBITOR 1 AG [UNITS/VOLUME] IN PLATELET POOR PLASMA BY IMMUNOASSAY
59835-9,PARATHYRIN.INTACT [MASS/VOLUME] IN BODY FLUID
6006-1,PROTEIN C [UNITS/VOLUME] IN PLATELET POOR PLASMA BY CHROMOGENIC METHOD
6010-3,PROTEIN C INHIBITOR [MASS/VOLUME] IN PLATELET POOR PLASMA BY IMMUNOASSAY
6014-5,VON WILLEBRAND FACTOR (VWF) RISTOCETIN COFACTOR ACTUAL/NORMAL IN PLATELET POOR PLASMA BY AGGREGATION
6019-4,ALMOND IGE AB [UNITS/VOLUME] IN SERUM
6020-2,ALTERNARIA ALTERNATA IGE AB [UNITS/VOLUME] IN SERUM
6021-0,APPLE IGE AB [UNITS/VOLUME] IN SERUM
6025-1,ASPERGILLUS FUMIGATUS IGE AB [UNITS/VOLUME] IN SERUM
60276-3,OXYCODONE+OXYMORPHONE CUTOFF [MASS/VOLUME] IN URINE FOR SCREEN METHOD
6029-3,AUREOBASIDIUM PULLULANS IGE AB [UNITS/VOLUME] IN SERUM
6033-5,AVOCADO IGE AB [UNITS/VOLUME] IN SERUM
6034-3,BAHIA GRASS IGE AB [UNITS/VOLUME] IN SERUM
6035-0,BANANA IGE AB [UNITS/VOLUME] IN SERUM
6037-6,BARLEY IGE AB [UNITS/VOLUME] IN SERUM
6039-2,BEEF IGE AB [UNITS/VOLUME] IN SERUM
6041-8,BERMUDA GRASS IGE AB [UNITS/VOLUME] IN SERUM
6045-9,BLACK PEPPER IGE AB [UNITS/VOLUME] IN SERUM
60465-2,NEISSERIA MENINGITIDIS W135 IGG AB [MASS/VOLUME] IN SERUM BY IMMUNOASSAY
60466-0,NEISSERIA MENINGITIDIS Y IGG AB [MASS/VOLUME] IN SERUM BY IMMUNOASSAY
6048-3,BLUE MUSSEL IGE AB [UNITS/VOLUME] IN SERUM
6050-9,BRAZIL NUT IGE AB [UNITS/VOLUME] IN SERUM
6052-5,BROCCOLI IGE AB [UNITS/VOLUME] IN SERUM
6059-0,CANDIDA ALBICANS IGE AB [UNITS/VOLUME] IN SERUM
6061-6,CARROT IGE AB [UNITS/VOLUME] IN SERUM
6062-4,CASEIN IGE AB [UNITS/VOLUME] IN SERUM
6065-7,CELERY IGE AB [UNITS/VOLUME] IN SERUM
6067-3,CHEESE CHEDDAR TYPE IGE AB [UNITS/VOLUME] IN SERUM
6070-7,CHICKEN FEATHER IGE AB [UNITS/VOLUME] IN SERUM
6073-1,CHOCOLATE IGE AB [UNITS/VOLUME] IN SERUM
6075-6,CLADOSPORIUM HERBARUM IGE AB [UNITS/VOLUME] IN SERUM
6076-4,CLAM IGE AB [UNITS/VOLUME] IN SERUM
6078-0,COCKROACH IGE AB [UNITS/VOLUME] IN SERUM
6081-4,COCONUT IGE AB [UNITS/VOLUME] IN SERUM
6082-2,CODFISH IGE AB [UNITS/VOLUME] IN SERUM
6083-0,COFFEE IGE AB [UNITS/VOLUME] IN SERUM
6085-5,COMMON RAGWEED IGE AB [UNITS/VOLUME] IN SERUM
6087-1,CORN IGE AB [UNITS/VOLUME] IN SERUM
6090-5,COTTONWOOD IGE AB [UNITS/VOLUME] IN SERUM
6092-1,CRAB IGE AB [UNITS/VOLUME] IN SERUM
6095-4,AMERICAN HOUSE DUST MITE IGE AB [UNITS/VOLUME] IN SERUM
6096-2,EUROPEAN HOUSE DUST MITE IGE AB [UNITS/VOLUME] IN SERUM
6097-0,DANDELION IGE AB [UNITS/VOLUME] IN SERUM
60981-8,AORTA BLOOD PRESSURE
60983-4,AORTA MEAN BLOOD PRESSURE
6098-8,DOG DANDER IGE AB [UNITS/VOLUME] IN SERUM
61031-1,7-AMINOCLONAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61034-5,7-AMINOFLUNITRAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61037-8,ALPHA HYDROXYALPRAZOLAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61038-6,ALPRAZOLAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61039-4,CLONAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61041-0,N-DESALKYLFLURAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61042-8,FENTANYL [PRESENCE] IN UNSPECIFIED SPECIMEN
61044-4,LORAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61046-9,METHYLENEDIOXYAMPHETAMINE [PRESENCE] IN UNSPECIFIED SPECIMEN
61049-3,METHYLENEDIOXYETHYLAMPHETAMINE [PRESENCE] IN UNSPECIFIED SPECIMEN
61051-9,NORDIAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61055-0,OXAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61061-8,TEMAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
6106-9,EGG WHITE IGE AB [UNITS/VOLUME] IN SERUM
61074-1,DIAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
6107-7,EGG YOLK IGE AB [UNITS/VOLUME] IN SERUM
61079-0,FLUNITRAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
61080-8,FLURAZEPAM [PRESENCE] IN UNSPECIFIED SPECIMEN
6109-3,WHITE ELM IGE AB [UNITS/VOLUME] IN SERUM
61093-1,TRIAZOLAM [PRESENCE] IN UNSPECIFIED SPECIMEN
6110-1,ENGLISH PLANTAIN IGE AB [UNITS/VOLUME] IN SERUM
6111-9,EPICOCCUM PURPURASCENS IGE AB [UNITS/VOLUME] IN SERUM
6117-6,RED IMPORTED FIRE ANT IGE AB [UNITS/VOLUME] IN SERUM
61177-2,PARANEOPLASTIC AB [PRESENCE] IN SERUM BY IMMUNOFLUORESCENCE
6121-8,FUSARIUM MONILIFORME IGE AB [UNITS/VOLUME] IN SERUM
6122-6,GARLIC IGE AB [UNITS/VOLUME] IN SERUM
6124-2,GIANT RAGWEED IGE AB [UNITS/VOLUME] IN SERUM
6125-9,GLUTEN IGE AB [UNITS/VOLUME] IN SERUM
6131-7,GRAPEFRUIT IGE AB [UNITS/VOLUME] IN SERUM
6136-6,HAZELNUT IGE AB [UNITS/VOLUME] IN SERUM
6138-2,SETOMELANOMMA ROSTRATA IGE AB [UNITS/VOLUME] IN SERUM
6141-6,HOP IGE AB [UNITS/VOLUME] IN SERUM
61430-5,AQUAPORIN 4 RECEPTOR AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
6152-3,JOHNSON GRASS IGE AB [UNITS/VOLUME] IN SERUM
6153-1,KENTUCKY BLUE GRASS IGE AB [UNITS/VOLUME] IN SERUM
6154-9,KIWIFRUIT IGE AB [UNITS/VOLUME] IN SERUM
6155-6,LAMB IGE AB [UNITS/VOLUME] IN SERUM
6156-4,GOOSEFOOT IGE AB [UNITS/VOLUME] IN SERUM
6158-0,LATEX IGE AB [UNITS/VOLUME] IN SERUM
6159-8,LEMON IGE AB [UNITS/VOLUME] IN SERUM
6161-4,LETTUCE IGE AB [UNITS/VOLUME] IN SERUM
6164-8,VIRGINIA LIVE OAK IGE AB [UNITS/VOLUME] IN SERUM
6165-5,LOBSTER IGE AB [UNITS/VOLUME] IN SERUM
6166-3,MALT IGE AB [UNITS/VOLUME] IN SERUM
6167-1,MANGO IGE AB [UNITS/VOLUME] IN SERUM
6169-7,MEADOW FESCUE IGE AB [UNITS/VOLUME] IN SERUM
6178-8,MOUNTAIN JUNIPER IGE AB [UNITS/VOLUME] IN SERUM
6179-6,MOUSE EPITHELIUM IGE AB [UNITS/VOLUME] IN SERUM
6182-0,MUCOR RACEMOSUS IGE AB [UNITS/VOLUME] IN SERUM
6185-3,MUSTARD IGE AB [UNITS/VOLUME] IN SERUM
6188-7,NUTMEG IGE AB [UNITS/VOLUME] IN SERUM
6189-5,WHITE OAK IGE AB [UNITS/VOLUME] IN SERUM
6190-3,OAT IGE AB [UNITS/VOLUME] IN SERUM
6193-7,ONION IGE AB [UNITS/VOLUME] IN SERUM
6194-5,ORANGE IGE AB [UNITS/VOLUME] IN SERUM
6195-2,COCKSFOOT IGE AB [UNITS/VOLUME] IN SERUM
6198-6,PAPER WASP IGE AB [UNITS/VOLUME] IN SERUM
6203-4,PARSLEY IGE AB [UNITS/VOLUME] IN SERUM
6204-2,PEA IGE AB [UNITS/VOLUME] IN SERUM
6205-9,PEACH IGE AB [UNITS/VOLUME] IN SERUM
6206-7,PEANUT IGE AB [UNITS/VOLUME] IN SERUM
6207-5,PEAR IGE AB [UNITS/VOLUME] IN SERUM
6208-3,PECAN OR HICKORY NUT IGE AB [UNITS/VOLUME] IN SERUM
6209-1,PECAN OR HICKORY TREE IGE AB [UNITS/VOLUME] IN SERUM
6210-9,PENICILLIN V IGE AB [UNITS/VOLUME] IN SERUM
6212-5,PENICILLIUM NOTATUM IGE AB [UNITS/VOLUME] IN SERUM
6218-2,PINEAPPLE IGE AB [UNITS/VOLUME] IN SERUM
6219-0,PORK IGE AB [UNITS/VOLUME] IN SERUM
6220-8,POTATO IGE AB [UNITS/VOLUME] IN SERUM
6224-0,RAT EPITHELIUM IGE AB [UNITS/VOLUME] IN SERUM
6228-1,RED TOP GRASS IGE AB [UNITS/VOLUME] IN SERUM
62292-8,25-HYDROXYVITAMIN D2+25-HYDROXYVITAMIN D3 [MASS/VOLUME] IN SERUM OR PLASMA
6229-9,RHIZOPUS NIGRICANS IGE AB [UNITS/VOLUME] IN SERUM
6230-7,RICE IGE AB [UNITS/VOLUME] IN SERUM
6234-9,SALTWORT IGE AB [UNITS/VOLUME] IN SERUM
6237-2,SALMON IGE AB [UNITS/VOLUME] IN SERUM
6242-2,SESAME SEED IGE AB [UNITS/VOLUME] IN SERUM
6244-8,SHEEP SORREL IGE AB [UNITS/VOLUME] IN SERUM
6246-3,SHRIMP IGE AB [UNITS/VOLUME] IN SERUM
62467-6,GALACTOMANNAN AG [UNITS/VOLUME] IN UNSPECIFIED SPECIMEN BY IMMUNOASSAY
6248-9,SOYBEAN IGE AB [UNITS/VOLUME] IN SERUM
6257-0,STRAWBERRY IGE AB [UNITS/VOLUME] IN SERUM
6258-8,SUNFLOWER SEED IGE AB [UNITS/VOLUME] IN SERUM
6259-6,CHESTNUT IGE AB [UNITS/VOLUME] IN SERUM
6260-4,SWEET GUM IGE AB [UNITS/VOLUME] IN SERUM
6263-8,AMERICAN SYCAMORE IGE AB [UNITS/VOLUME] IN SERUM
6264-6,TEA IGE AB [UNITS/VOLUME] IN SERUM
6265-3,TIMOTHY IGE AB [UNITS/VOLUME] IN SERUM
6266-1,TOMATO IGE AB [UNITS/VOLUME] IN SERUM
6268-7,TROUT IGE AB [UNITS/VOLUME] IN SERUM
6270-3,TUNA IGE AB [UNITS/VOLUME] IN SERUM
6271-1,TURKEY MEAT IGE AB [UNITS/VOLUME] IN SERUM
6273-7,WALNUT IGE AB [UNITS/VOLUME] IN SERUM
6274-5,CALIFORNIA WALNUT IGE AB [UNITS/VOLUME] IN SERUM
6276-0,WHEAT IGE AB [UNITS/VOLUME] IN SERUM
6278-6,WHITE ASH IGE AB [UNITS/VOLUME] IN SERUM
6279-4,WHITE BEAN IGE AB [UNITS/VOLUME] IN SERUM
6280-2,WHITEFACED HORNET IGE AB [UNITS/VOLUME] IN SERUM
6281-0,WHITE MULBERRY IGE AB [UNITS/VOLUME] IN SERUM
6285-1,WILLOW IGE AB [UNITS/VOLUME] IN SERUM
6286-9,WORMWOOD IGE AB [UNITS/VOLUME] IN SERUM
6288-5,YELLOW HORNET IGE AB [UNITS/VOLUME] IN SERUM
6298-4,POTASSIUM [MOLES/VOLUME] IN BLOOD
6301-6,INR
6318-0,BORRELIA BURGDORFERI AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID BY IMMUNOASSAY
6320-6,BORRELIA BURGDORFERI IGG AB [PRESENCE] IN SERUM BY IMMUNOBLOT
6321-4,BORRELIA BURGDORFERI IGM AB [PRESENCE] IN SERUM BY IMMUNOBLOT
63329-7,RNA POLYMERASE III AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
63420-4,GLIADIN PEPTIDE+TISSUE TRANSGLUTAMINASE IGA+IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
63432-9,HERPES SIMPLEX VIRUS 1+2 IGM AB [UNITS/VOLUME] IN CEREBRAL SPINAL FLUID
6349-5,CHLAMYDIA TRACHOMATIS [PRESENCE] IN UNSPECIFIED SPECIMEN BY ORGANISM SPECIFIC CULTURE
6371-9,CRYPTOSPORIDIUM SP AG [PRESENCE] IN STOOL BY IMMUNOASSAY
64084-7,MYCOBACTERIUM TUBERCULOSIS STIMULATED GAMMA INTERFERON [UNITS/VOLUME] CORRECTED FOR BACKGROUND IN BLOOD
6412-1,GIARDIA LAMBLIA AG [PRESENCE] IN STOOL BY IMMUNOASSAY
6433-7,HTLV I IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
6447-7,LEGIONELLA PNEUMOPHILA AG [PRESENCE] IN URINE BY IMMUNOASSAY
6476-6,MUMPS VIRUS IGG AB [PRESENCE] IN SERUM BY IMMUNOASSAY
649-4,MICROSCOPIC OBSERVATION [IDENTIFIER] IN STOOL BY GRAM STAIN
653-6,MICROSCOPIC OBSERVATION [IDENTIFIER] IN URINE BY GRAM STAIN
65818-7,MEDICATION [MASS/VOLUME] DOSE
6598-7,TROPONIN T.CARDIAC [MASS/VOLUME] IN SERUM OR PLASMA
664-3,MICROSCOPIC OBSERVATION [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY GRAM STAIN
6644-9,CEFEPIME [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
66502-6,HBA1 GENE TARGETED MUTATION ANALYSIS IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD NARRATIVE
6652-2,MEROPENEM [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
6653-0,MEROPENEM [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
6667-0,MICROSCOPIC OBSERVATION [IDENTIFIER] IN TISSUE BY KOH PREPARATION
66746-9,SPECIMEN TYPE
66748-5,CLOT ANGLE IN BLOOD BY THROMBOELASTOGRAPHY
66751-9,CLOT STRENGTH IN BLOOD BY THROMBOELASTOGRAPHY
667-6,MICROSCOPIC OBSERVATION [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY KOH PREPARATION
6683-7,REPTILASE TIME
6687-8,CITRATE [MASS/TIME] IN 24 HOUR URINE
6690-2,LEUKOCYTES [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
6693-6,MERCURY [MASS/TIME] IN 24 HOUR URINE
6694-4,QUINIDINE [MASS/VOLUME] IN SERUM OR PLASMA
6718-1,CASHEW NUT IGE AB [UNITS/VOLUME] IN SERUM
6719-9,CHERRY IGE AB [UNITS/VOLUME] IN SERUM
6724-9,CUCUMBER IGE AB [UNITS/VOLUME] IN SERUM
6733-0,PIGEON SERUM AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
673-4,OVA AND PARASITES IDENTIFIED IN UNSPECIFIED SPECIMEN BY LIGHT MICROSCOPY
6740-5,YELLOW JACKET IGE AB [UNITS/VOLUME] IN SERUM
6741-3,ERYTHROCYTES [#/VOLUME] IN BODY FLUID BY MANUAL COUNT
6744-7,LYMPHOCYTES [#/VOLUME] IN BODY FLUID BY MANUAL COUNT
6766-0,17-KETOSTEROIDS [MASS/TIME] IN 24 HOUR URINE
6768-6,ALKALINE PHOSPHATASE SERUM/PLASMA
6774-4,DESETHYLAMIODARONE [MASS/VOLUME] IN SERUM OR PLASMA
678-3,MICROSCOPIC OBSERVATION [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY TRICHROME STAIN
6808-0,ASPERGILLUS FUMIGATUS 1 AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
6809-8,ASPERGILLUS FUMIGATUS 6 AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
6810-6,AUREOBASIDIUM PULLULANS AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
681-7,MICROSCOPIC OBSERVATION [IDENTIFIER] IN UNSPECIFIED SPECIMEN BY WRIGHT STAIN
6818-9,SACCHAROPOLYSPORA RECTIVIRGULA AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
6821-3,THERMOACTINOMYCES VULGARIS AB [PRESENCE] IN SERUM BY IMMUNE DIFFUSION (ID)
6830-4,ASPERGILLUS NIGER IGE AB [UNITS/VOLUME] IN SERUM
6831-2,GREEN BEAN IGE AB [UNITS/VOLUME] IN SERUM
6833-8,CAT DANDER IGE AB [UNITS/VOLUME] IN SERUM
6836-1,CHICKEN SERUM PROTEINS IGE AB [UNITS/VOLUME] IN SERUM
6837-9,CINNAMON IGE AB [UNITS/VOLUME] IN SERUM
68383-9,MICROSCOPIC OBSERVATION [IDENTIFIER] IN BODY FLUID BY KOH PREPARATION
6841-1,GRAPE IGE AB [UNITS/VOLUME] IN SERUM
6842-9,HALIBUT IGE AB [UNITS/VOLUME] IN SERUM
6844-5,HONEY BEE IGE AB [UNITS/VOLUME] IN SERUM
6848-6,MUSHROOM IGE AB [UNITS/VOLUME] IN SERUM
6853-6,PLUM IGE AB [UNITS/VOLUME] IN SERUM
68549-5,U2 SMALL NUCLEAR RIBONUCLEOPROTEIN AB [PRESENCE] IN SERUM
6856-9,SPINACH IGE AB [UNITS/VOLUME] IN SERUM
6864-3,HEMOGLOBIN S [PRESENCE] IN BLOOD BY SOLUBILITY TEST
6873-4,BETA HYDROXYBUTYRATE [MOLES/VOLUME] IN SERUM OR PLASMA
6874-2,CALCIUM [MASS/TIME] IN 24 HOUR URINE
6875-9,CANCER AG 15-3 [UNITS/VOLUME] IN SERUM OR PLASMA
6884-1,HOMOCYSTINE [MASS/TIME] IN 24 HOUR URINE
6886-6,IGA SUBCLASS 1 [MASS/VOLUME] IN SERUM
6892-4,THYROXINE (T4) FREE [MASS/VOLUME] IN SERUM OR PLASMA BY DIALYSIS
6896-5,CLOZAPINE [MASS/VOLUME] IN SERUM OR PLASMA
6899-9,FELBAMATE SERUM/PLASMA
6912-0,CHLAMYDOPHILA PNEUMONIAE IGA AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6913-8,CHLAMYDOPHILA PNEUMONIAE IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6914-6,CHLAMYDOPHILA PNEUMONIAE IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6915-3,CHLAMYDOPHILA PSITTACI IGA AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6916-1,CHLAMYDOPHILA PSITTACI IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6917-9,CHLAMYDOPHILA PSITTACI IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6920-3,CHLAMYDIA TRACHOMATIS IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6928-6,RHEUMATOID FACTOR [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
6929-4,ALUMINUM [MASS/VOLUME] IN 24 HOUR URINE
6933-6,STREPTOMYCIN.HIGH POTENCY [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
69367-1,BORDETELLA PERTUSSIS IGG AB [PRESENCE] IN SERUM BY IMMUNOBLOT
6939-3,IGA SUBCLASS 2 [MASS/VOLUME] IN SERUM
6942-7,ALBUMIN [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
6944-3,GLIPIZIDE [MASS/VOLUME] IN UNSPECIFIED SPECIMEN
6945-0,GLYBURIDE [MASS/VOLUME] IN UNSPECIFIED SPECIMEN
6948-4,LAMOTRIGINE SERUM/PLASMA
6951-8,TOLAZAMIDE [MASS/VOLUME] IN UNSPECIFIED SPECIMEN
6952-6,TOLBUTAMIDE [MASS/VOLUME] IN UNSPECIFIED SPECIMEN
6954-2,BARTONELLA HENSELAE IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6955-9,BARTONELLA HENSELAE IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
6968-2,PROTEINASE 3 AB [UNITS/VOLUME] IN SERUM
6969-0,MYELOPEROXIDASE AB [UNITS/VOLUME] IN SERUM
6970-8,PURKINJE CELLS AB [TITER] IN SERUM
6979-9,AMPICILLIN [SUSCEPTIBILITY] BY GRADIENT STRIP
6989-8,CEFOTAXIME [SUSCEPTIBILITY] BY GRADIENT STRIP
7002-9,CIPROFLOXACIN [SUSCEPTIBILITY] BY GRADIENT STRIP
70121-9,FRANCISELLA TULARENSIS IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA
7013-6,FLUCONAZOLE [SUSCEPTIBILITY] BY GRADIENT STRIP
70138-3,AMPHETAMINES [MASS/VOLUME] IN URINE BY SCREEN METHOD
70140-9,BENZODIAZEPINES [MASS/VOLUME] IN URINE BY SCREEN METHOD
70143-3,CANNABINOIDS [MASS/VOLUME] IN URINE BY SCREEN METHOD
70149-0,METHADONE [PRESENCE] IN URINE BY SCREEN METHOD >300 NG/ML
70155-7,BARBITURATES [PRESENCE] IN URINE BY SCREEN METHOD >200 NG/ML
7016-9,GENTAMICIN [SUSCEPTIBILITY] BY GRADIENT STRIP
7018-5,GENTAMICIN.HIGH POTENCY [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
7026-8,LEVOFLOXACIN [SUSCEPTIBILITY] BY GRADIENT STRIP
7029-2,MEROPENEM [SUSCEPTIBILITY] BY GRADIENT STRIP
7041-7,PENICILLIN G [SUSCEPTIBILITY] BY GRADIENT STRIP
704-7,BASOPHILS [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
705-4,BASOPHILS [#/VOLUME] IN BLOOD BY MANUAL COUNT
7057-3,TRIMETHOPRIM+SULFAMETHOXAZOLE [SUSCEPTIBILITY] BY GRADIENT STRIP
7059-9,VANCOMYCIN [SUSCEPTIBILITY] BY GRADIENT STRIP
706-2,BASOPHILS/100 LEUKOCYTES IN BLOOD BY AUTOMATED COUNT
707-0,BASOPHILS/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
7091-2,APRICOT IGE AB [UNITS/VOLUME] IN SERUM
709-6,BLASTS/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
7099-5,ASPARAGUS IGE AB [UNITS/VOLUME] IN SERUM
7103-5,ASPERGILLUS FUMIGATUS IGG AB [UNITS/VOLUME] IN SERUM
711-2,EOSINOPHILS [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
712-0,EOSINOPHILS [#/VOLUME] IN BLOOD BY MANUAL COUNT
7129-0,RED KIDNEY BEAN IGE AB [UNITS/VOLUME] IN SERUM
7131-6,LIMA BEAN IGE AB [UNITS/VOLUME] IN SERUM
713-8,EOSINOPHILS/100 LEUKOCYTES IN BLOOD BY AUTOMATED COUNT
714-6,EOSINOPHILS/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
7152-2,BLUEBERRY IGE AB [UNITS/VOLUME] IN SERUM
7155-5,BOXELDER IGE AB [UNITS/VOLUME] IN SERUM
71693-6,PLATELETS RETICULATED/100 PLATELETS IN BLOOD BY AUTOMATED COUNT
7169-6,CABBAGE IGE AB [UNITS/VOLUME] IN SERUM
71773-6,MYCOBACTERIUM TUBERCULOSIS STIMULATED GAMMA INTERFERON [PRESENCE] IN BLOOD
71774-4,MITOGEN STIMULATED GAMMA INTERFERON [UNITS/VOLUME] CORRECTED FOR BACKGROUND IN BLOOD
71776-9,GAMMA INTERFERON BACKGROUND [UNITS/VOLUME] IN BLOOD BY IMMUNOASSAY
718-7,HEMOGLOBIN
7187-8,CATFISH IGE AB [UNITS/VOLUME] IN SERUM
721-1,FREE HEMOGLOBIN [MASS/VOLUME] IN PLASMA
72493-0,CYTOMEGALOVIRUS DNA [UNITS/VOLUME] (VIRAL LOAD) IN PLASMA BY PROBE AND TARGET AMPLIFICATION METHOD
7258-7,COW MILK IGE AB [UNITS/VOLUME] IN SERUM
72623-2,INFLIXIMAB AB [MASS/VOLUME] IN SERUM OR PLASMA
7262-9,CRANBERRY IGE AB [UNITS/VOLUME] IN SERUM
7271-0,CURVULARIA SP IGE AB [UNITS/VOLUME] IN SERUM
7280-1,DILL IGE AB [UNITS/VOLUME] IN SERUM
72854-3,GANCICLOVIR [SUSCEPTIBILITY] BY GENOTYPE METHOD
72856-8,CIDOFOVIR [SUSCEPTIBILITY] BY GENOTYPE METHOD
7291-8,WHOLE EGG IGE AB [UNITS/VOLUME] IN SERUM
7296-7,EGGPLANT IGE AB [UNITS/VOLUME] IN SERUM
731-0,LYMPHOCYTES [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
7312-2,FLAX IGE AB [UNITS/VOLUME] IN SERUM
7316-3,FLOUNDER IGE AB [UNITS/VOLUME] IN SERUM
735-1,VARIANT LYMPHOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
73681-9,CYP2D6 GENE ALLELE 2 [IDENTIFIER] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD
73682-7,CYP2D6 GENE ALLELE 1 [IDENTIFIER] IN BLOOD OR TISSUE BY MOLECULAR GENETICS METHOD
736-9,LYMPHOCYTES/100 LEUKOCYTES IN BLOOD BY AUTOMATED COUNT
7369-2,PERENNIAL RYE GRASS IGE AB [UNITS/VOLUME] IN SERUM
737-7,LYMPHOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
740-1,METAMYELOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
7415-3,CLADOSPORIUM SPHAEROSPERMUM IGE AB [UNITS/VOLUME] IN SERUM
7425-2,HOUSE DUST HOLLISTER STIER IGE AB [UNITS/VOLUME] IN SERUM
742-7,MONOCYTES [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
743-5,MONOCYTES [#/VOLUME] IN BLOOD BY MANUAL COUNT
744-3,MONOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
74444-1,THIAMINE PYROPHOSPHATE [MOLES/VOLUME] IN BLOOD
7464-1,LIME IGE AB [UNITS/VOLUME] IN SERUM
7484-9,BURWEED MARSHELDER IGE AB [UNITS/VOLUME] IN SERUM
749-2,MYELOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
751-8,NEUTROPHILS [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
753-4,NEUTROPHILS [#/VOLUME] IN BLOOD BY MANUAL COUNT
7552-3,OREGANO IGE AB [UNITS/VOLUME] IN SERUM
7558-0,OYSTER IGE AB [UNITS/VOLUME] IN SERUM
7565-5,PARAKEET FEATHER IGE AB [UNITS/VOLUME] IN SERUM
75666-8,"HIV 1+2 AB AND HIV1 P24 AG [IDENTIFIER] IN SERUM, PLASMA OR BLOOD BY RAPID IMMUNOASSAY"
7573-9,CHICK PEA IGE AB [UNITS/VOLUME] IN SERUM
7586-1,BELL PEPPER IGE AB [UNITS/VOLUME] IN SERUM
76-0,CEFAZOLIN [SUSCEPTIBILITY] BY MINIMUM INHIBITORY CONCENTRATION (MIC)
7604-2,COMMON PIGWEED IGE AB [UNITS/VOLUME] IN SERUM
7613-3,PISTACHIO IGE AB [UNITS/VOLUME] IN SERUM
76171-8,RESPIRATORY RATE BY AIRWAY FLOW MEASUREMENT
76212-0,INVASIVE BLOOD PRESSURE
76213-8,INVASIVE DIASTOLIC BLOOD PRESSURE
76214-6,INVASIVE MEAN BLOOD PRESSURE
76215-3,INVASIVE SYSTOLIC BLOOD PRESSURE
7623-2,POPPY SEED IGE AB [UNITS/VOLUME] IN SERUM
7627-3,SWEET POTATO IGE AB [UNITS/VOLUME] IN SERUM
7632-3,PRIVET IGE AB [UNITS/VOLUME] IN SERUM
76533-9,BLOOD PRESSURE BY NONINVASIVE
76534-7,SYSTOLIC BLOOD PRESSURE BY NONINVASIVE
76535-4,DIASTOLIC BLOOD PRESSURE BY NONINVASIVE
76536-2,MEAN BLOOD PRESSURE BY NONINVASIVE
76634-5,Q-T INTERVAL CORRECTED BASED ON FRIDERICIA FORMULA
76635-2,Q-T INTERVAL CORRECTED BASED ON BAZETT FORMULA
7674-5,RYE IGE AB [UNITS/VOLUME] IN SERUM
7678-6,SAGE IGE AB [UNITS/VOLUME] IN SERUM
7691-9,SCALLOP IGE AB [UNITS/VOLUME] IN SERUM
770-8,NEUTROPHILS/100 LEUKOCYTES IN BLOOD BY AUTOMATED COUNT
771-6,NUCLEATED ERYTHROCYTES [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
7718-0,ZUCCHINI IGE AB [UNITS/VOLUME] IN SERUM
77205-3,BUPRENORPHINE [PRESENCE] IN MECONIUM BY SCREEN METHOD
7728-9,SWORDFISH IGE AB [UNITS/VOLUME] IN SERUM
77307-7,LEAD [MASS/VOLUME] IN VENOUS BLOOD
7737-0,THYME IGE AB [UNITS/VOLUME] IN SERUM
7756-0,VANILLA IGE AB [UNITS/VOLUME] IN SERUM
7770-1,WATERMELON IGE AB [UNITS/VOLUME] IN SERUM
777-3,PLATELETS [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
7774-3,COW WHEY IGE AB [UNITS/VOLUME] IN SERUM
7775-0,WHITEFISH IGE AB [UNITS/VOLUME] IN SERUM
7827-9,COCCIDIOIDES IMMITIS IGM AB [UNITS/VOLUME] IN SERUM
783-1,PROMYELOCYTES/100 LEUKOCYTES IN BLOOD BY MANUAL COUNT
7853-5,CYTOMEGALOVIRUS IGM AB [UNITS/VOLUME] IN SERUM
785-6,ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN [ENTITIC MASS] BY AUTOMATED COUNT
786-4,ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION [MASS/VOLUME] BY AUTOMATED COUNT
787-2,ERYTHROCYTE MEAN CORPUSCULAR VOLUME [ENTITIC VOLUME] BY AUTOMATED COUNT
788-0,ERYTHROCYTE DISTRIBUTION WIDTH [RATIO] BY AUTOMATED COUNT
7891-5,GIARDIA LAMBLIA IGG AB [UNITS/VOLUME] IN SERUM
7892-3,GIARDIA LAMBLIA IGM AB [UNITS/VOLUME] IN SERUM
789-8,ERYTHROCYTES [#/VOLUME] IN BLOOD BY AUTOMATED COUNT
7917-8,HIV 1 AB [PRESENCE] IN SERUM
79182-2,RNA POLYMERASE III IGG AB [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
792-2,ERYTHROCYTES [#/VOLUME] IN CEREBRAL SPINAL FLUID BY MANUAL COUNT
79348-9,BODY WEIGHT --USED FOR DRUG CALCULATION
7959-0,LEPTOSPIRA SP AB [TITER] IN SERUM
7962-4,MEASLES VIRUS IGG
797-1,ERYTHROCYTES [#/VOLUME] IN SYNOVIAL FLUID BY MANUAL COUNT
8014-3,RUBELLA VIRUS IGG
80221-5,NMDAR IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
8039-0,TOXOPLASMA GONDII IGG AB [UNITS/VOLUME] IN SERUM
8040-8,TOXOPLASMA GONDII IGM AB [UNITS/VOLUME] IN SERUM
804-5,LEUKOCYTES [#/VOLUME] IN BLOOD BY MANUAL COUNT
80697-6,MYCOPHENOLATE ACYL-GLUCURONIDE [MASS/VOLUME] IN SERUM OR PLASMA
8074-7,INSULIN HUMAN AB [UNITS/VOLUME] IN SERUM
8077-0,MITOCHONDRIA AB [UNITS/VOLUME] IN SERUM
8098-6,THYROGLOBULIN AB [UNITS/VOLUME] IN SERUM OR PLASMA
8099-4,THYROPEROXIDASE AB [UNITS/VOLUME] IN SERUM OR PLASMA
8117-4,CD19 CELLS/100 CELLS IN BLOOD
8123-2,CD3+CD4+ (T4 HELPER) CELLS/100 CELLS IN BLOOD
8131-5,CD5+CD19+ CELLS/100 CELLS IN BLOOD
8146-3,AMPHETAMINES [PRESENCE] IN MECONIUM BY SCREEN METHOD
8169-5,TETRAHYDROCANNABINOL [PRESENCE] IN MECONIUM BY SCREEN METHOD
8216-4,OPIATES [PRESENCE] IN MECONIUM BY SCREEN METHOD
8234-7,PHENCYCLIDINE [PRESENCE] IN MECONIUM BY SCREEN METHOD
8246-1,AMORPHOUS SEDIMENT [PRESENCE] IN URINE SEDIMENT BY LIGHT MICROSCOPY
8251-1,SERVICE COMMENT
8272-7,CEFEPIME [SUSCEPTIBILITY] BY DISK DIFFUSION (KB)
8301-4,BODY HEIGHT ESTIMATED
83084-4,CANCER AG 19-9 [UNITS/VOLUME] IN SERUM OR PLASMA BY IMMUNOASSAY
8328-7,AXILLARY TEMPERATURE
8329-5,BODY TEMPERATURE - CORE
8331-1,ORAL TEMPERATURE
8332-9,RECTAL TEMPERATURE
8333-7,TYMPANIC MEMBRANE TEMPERATURE
8339-4,BIRTH WEIGHT MEASURED
8340-2,DRY BODY WEIGHT ESTIMATED
8345-1,BODY WEIGHT MEASURED --POST PARTUM
8626-4,P WAVE AXIS
8627-2,P WAVE DURATION
8632-2,QRS AXIS
8633-0,QRS DURATION
8634-8,Q-T INTERVAL
8636-3,Q-T INTERVAL CORRECTED
8637-1,R-R INTERVAL BY EKG
8638-9,T WAVE AXIS
8852-6,MAIN PULMONARY ARTERY OXYGEN SATURATION
8884-9,HEART RATE RHYTHM
8889-8,HEART RATE - OXIMETER
8894-8,P WAVE ATRIUM BY EKG
9271-8,10 MINUTE APGAR SCORE
9272-6,1 MINUTE APGAR SCORE
9274-2,5 MINUTE APGAR SCORE
9306-2,POLYMORPHONUCLEAR CELLS/100 LEUKOCYTES IN BODY FLUID BY MANUAL COUNT
9335-1,APPEARANCE OF BODY FLUID
9362-5,BORDETELLA PERTUSSIS IGA AB [UNITS/VOLUME] IN SERUM
9383-1,9-HYDROXYRISPERIDONE [MASS/VOLUME] IN SERUM OR PLASMA
9393-0,RISPERIDONE [MASS/VOLUME] IN SERUM OR PLASMA
9394-8,RISPERIDONE+9-HYDROXYRISPERIDONE [MASS/VOLUME] IN SERUM OR PLASMA
9410-2,HISTAMINE [MASS/TIME] IN 24 HOUR URINE
9412-8,LEUCINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
9423-5,NUCLEAR AB [UNITS/VOLUME] IN SERUM BY IMMUNOFLUORESCENCE
9453-2,HISTIDINE [MOLES/VOLUME] IN CEREBRAL SPINAL FLUID
9508-3,CHLOROTHIAZIDE [PRESENCE] IN URINE
9522-4,ENTAMOEBA HISTOLYTICA IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
9537-2,INTRINSIC FACTOR BLOCKING AB [PRESENCE] IN SERUM BY RADIOIMMUNOASSAY (RIA)
9622-2,PHYTONADIONE [MASS/VOLUME] IN SERUM OR PLASMA
9627-1,IMIPRAMINE+DESIPRAMINE [MASS/VOLUME] IN SERUM OR PLASMA
9641-2,CATECHOLAMINES/CREATININE [MASS RATIO] IN URINE
9656-0,ECHINOCOCCUS SP IGG AB [UNITS/VOLUME] IN SERUM BY IMMUNOASSAY
9658-6,GIARDIA LAMBLIA IGA AB [UNITS/VOLUME] IN SERUM
9734-5,ALPHA 1 GLOBULIN [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
9738-6,GABAPENTIN SERUM/PLASMA
9744-4,BETA GLOBULIN [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
9745-1,GAMMA GLOBULIN [MASS/VOLUME] IN URINE BY ELECTROPHORESIS
9757-6,COXSACKIEVIRUS A9 AB [TITER] IN SERUM BY COMPLEMENT FIXATION
9765-9,LYMPHOCYTIC CHORIOMENINGITIS VIRUS IGG AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
9767-5,LYMPHOCYTIC CHORIOMENINGITIS VIRUS IGM AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
9783-2,EHRLICHIA CHAFFEENSIS IGG AB [TITER] IN SERUM
9784-0,EHRLICHIA CHAFFEENSIS IGM AB [TITER] IN SERUM
9811-1,CHROMOGRANIN A [MASS/VOLUME] IN SERUM OR PLASMA
9817-8,CRYPTOCOCCUS SP AG [TITER] IN CEREBRAL SPINAL FLUID BY IMMUNOASSAY
9830-1,CHOLESTEROL.TOTAL/CHOLESTEROL IN HDL [MASS RATIO] IN SERUM OR PLASMA
9838-4,LIVER KIDNEY MICROSOMAL AB [TITER] IN SERUM BY IMMUNOFLUORESCENCE
1743-4,Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma by With P-5'-P
20405-7,Urobilinogen [Mass/volume] in Urine by Test strip
2148-5,Creatine [Mass/volume] in Serum or Plasma
49779-2,Ketones Ur-mCnc - Ketones [Mass/volume] in Urine
34532-2,Blood type and Indirect antibody screen panel - Blood
882-1,ABO and Rh group [Type] in Blood
883-9,ABO group [Type] in Blood
10331-7,Rh [Type] in Blood
77397-8,ABO and Rh group [Type] in Blood by Confirmatory method
LL2972-9,ABORh / ABO and Rh Grouping
34531-4,Blood type and Crossmatch panel - Blood